Nano state: tiny and now everywhere, how big a problem are nanoparticles? – The Guardian

In 2019, Ikea announced it had developed curtains that it claimed could break down common indoor air pollutants. The secret, it said, was the fabrics special coating. What if we could use textiles to clean the air? asked Ikeas product developer, Mauricio Affonso, in a promotional video for the Gunrid curtains.

After explaining that the coating was a photocatalyst (similar to photosynthesis, found in nature), Affonso is shown gazing up at the gauzy curtains while uplifting music plays. Its amazing to work on something that can give people the opportunity to live a healthier life at home.

Puzzled by these claims how could a mineral coating clean the air? Avicenn, a French environmental nonprofit organisation, investigated. Independent laboratory tests of the Gunrid textile reported that samples contained tiny particles of titanium dioxide (TiO2) a substance not normally toxic but which can be possibly carcinogenic if inhaled, and potentially in other forms which supposedly gives self-cleaning properties to things such as paint and windows when exposed to sunlight.

These tiny particles, or nanoparticles, are at the forefront of materials science. Nanoparticles come in all shapes spheres, cubes, fibres or sheets but the crucial thing is their size: they are smaller than 100 nanometres (a human hair is approximately 80,000nm thick).

Many nanoparticles exist in nature. Nano-hairs make a geckos feet sticky, and nano-proteins make a spiders silk strong. But they can be manufactured, and because they are so small, they have special properties that make them attractive across a range of endeavours not just to companies such as Ikea. In medicine, they can transport cancer drugs directly into tumour cells, and nanosilver is used to coat medical breathing tubes and bandages. Nanos could direct pesticides to parts of a plant, or release nutrients from fertilisers in a more controlled manner.

They also have more mundane uses. Synthetic nanos are added to cosmetics and food. Nanosilver is used in textiles, where it is claimed to give antibacterial properties to plasters, gym leggings, yoga mats and period pants.

But scientists such as those at Avicenn are concerned that when these household items get washed, recycled or thrown away, synthetic nanos are released into the environment making their way into the soil and sea in ways that are still not understood. Some scientists believe nanoparticles could pose an even greater threat than microplastics.

Synthetic nano particles of plastic have been found in the ocean and in ice on both poles. Nanoparticles from socks and sunscreen have been found to pollute water, and certain nanos have been shown to negatively affect marine wildlife including fish and crustaceans. As with antibiotics, resistance to antimicrobial nanosilver can develop silver-tolerant soil bacteria have now been found.

Little is known even about where nanoparticles are, let alone their effects on the environment. As they are so tiny, most experiments are conducted in labs, and it can be hard to pin down where they are applied.

The main problem with these substances is that we cannot measure them we know they are there but theyre so tiny theyre difficult to detect, which is why you dont hear as much about them, says Nick Voulvoulis, professor of environmental technology at Imperial College London.

He worries about the uncontrolled use of nanos in consumer products. If nanos are used properly in applications that are useful or beneficial, thats justified, but if they are used anywhere and everywhere because they have certain properties, thats crazy.

Synthetic nanoparticles are not inherently harmful. Like their natural cousins, many are metal-based, but they can be made of any substance. Crucially, unlike chemical compounds, they cannot be dissolved. Their tiny size gives them, paradoxically, an enormous surface area, which makes them behave differently to non-nano versions of the same material. It can make them more mobile, more reactive and potentially more toxic, depending on shape, size, type, how a substance is released into the environment and its concentration.

And released into the environment they are, on a massive scale. According to Avicenn, the release of nanos is most likely during manufacture or disposal, but it can also happen when items are washed which is known to occur with fabrics containing nanosilver. Sewage systems cannot trap them and they end up in the ocean: the OECD says even advanced wastewater-treatment plants cannot deal with nanoparticles.

From a health perspective, inhalation is the most harmful route of exposure to nanos such as TiO2 for factory workers and consumers. Avicenns tests concluded that the average particle size was 4.9nm, and all 300 particles analysed were below the official nano threshold of 100nm.

Ikea insisted its own tests showed the TiO2 particles were properly bound to the fabric and pose no risk to customers, and said it took workers safety extremely seriously. The firm has not referred to them as nanoparticles, and said that once integrated into textile surfaces there was no good standard method to measure the particle size distribution of a material, acknowledging that EU definitions of nanomaterials were under review.

We recognise that the tests and measurements of nano-particles are complex, especially for materials containing particles that tend to form agglomerates, it said.

As for Ikeas curtains shedding TiO2 nanoparticles when washed or discarded, Ikea said it was confident that the treatment is properly bound to the fabric, and therefore we do not see a risk of inhaling the treatment, but acknowledged that as with any textile, parts of the textile can come off during use or washing.

Many nanos do not persist for long in the environment. However, because they are consistently being discharged, levels remain fairly constant. Nanos are pseudo-persistent because they degrade quite quickly but they keep entering the environment, Voulvoulis says.

His main concern is whether nanos become carriers for other compounds, a subject of scientific debate. In 2009, Spanish scientists suggested nanos could bind to and transport toxic pollutants, and possibly be toxic themselves by generating reactive free radicals. If other toxic pollutants latch on to nanos surfaces, they argued, marine plants and animals could absorb them more easily.

Other scientists suggest the opposite: that organic matter in sewage coat nanoparticles, rendering them less active. And others fear nanos could trigger toxic cocktail effects making them more harmful in combination than individual substances would be separately.

So far, synthetic nanomaterials are relatively dispersed in the sea, and unlikely to significantly affect marine animals, says Dr Tobias Lammel of Gothenburg University, who has studied copper nanos. But he warns: Its possible that the concentration of some manufactured nanomaterials in the marine environment will increase It is important to keep an eye on this.

Given the huge question marks, Avicenn wants more stringent regulations on nanos, and more caution in product design. Companies are eager to sell innovative and fancy products, but they must thoroughly assess their benefits-risks balance at each step of the life-cycle of the products, says Mathilde Detcheverry, Avicenns policy manager.

From August, the EU will ban use of TiO2 nanos in food (where it is called E171) and the European Commission recently announced that 12 nanomaterials would soon be prohibited in cosmetics.

Detcheverry says: As scientific knowledge about the environmental and health impacts of engineered nanos such as silver and titanium dioxide advances, we need to make sure nanos are only allowed for specific and essential uses in order to minimise any adverse effects at the source and [ensure they are] not released uncontrollably.

Two years after the release of Ikeas Gunrid curtains, Avicenn tried to buy more for further tests, but they had been withdrawn from sale.

Ikea told the Guardian that Gunrid remained safe to use as a traditional curtain but it was withdrawn because the functionality was not as effective as expected. If thats true for example, that despite TiO2 having proven photocatalytic properties and being used in self-cleaning and air-purifying products, its efficacy on curtains could be localised and not powerful then at the very least Ikeas experience suggests nanoparticles benefits may not outweigh the potential and frequently unknown risks, Detcheverry says.

Nanoparticles are often promoted as silver bullets against pollution or bacteria, she says, but we must make sure that the cure is not worse than the disease.

Gunrid was just one product of many thousands that use nanoparticles. As Ikeas Affonso says in the video: Whats so great about Gunrid is that this technology could be applied to any textile.

This article was amended on 26 April 2022 to correct the spelling of Gothenburg.

Read the original post:
Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian

Tulane Professor Elected to National Academy of Inventors – bizneworleans.com

Chenzhong Li is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending. (Photo by Paula Burch Celentano.)

NEW ORLEANS From Tulane University:

Tulane University professor Chenzhong Li, PhD, has been named a 2021 fellow by the National Academy of Inventors (NAI), an honor that is the highest professional distinction accorded solely to academic inventors.

Li, professor of Biomedical Engineering and Biochemistry at Tulane University School of Medicine and the School of Science and Engineering, leads advances in biochemistry and biomedical engineering research at the Center for Cellular and Molecular Diagnostics. He was one of 164 prolific academic innovators from across the world elected as an NAI Fellow this year.

The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and the welfare of society.

I am delighted to be selected for a fellowship with the National Academy of Inventors, Li said. This is an amazing moment and one of the most important in my professional career. While I have only been a part of the Tulane family for a relatively short amount of time, this recognition gives me the inspiration to improve my work even more in translational research and entrepreneurship education for our faculty and students.

Li is a pioneer in the development of biosensors for cancer, neurological diseases and infectious disease diagnosis and treatment. He holds 16 U.S. and international patents with several more pending.

Li developed a carbon fiber micro biosensor array only a few micrometers in size to find Beta-amyloid proteins, a critical biomarker for Alzheimers disease. The needle-like nano biosensor can measure the biomarker at the single neuron level to help better understand Alzheimers progression and to fast screen potential drug treatments. He has also invented new technology using nanoparticles to find markers for cancer tumor growth.

Li has also worked as a professional research associate at the startup company Adnavance Technologies, Inc. in Canada where he led an entrepreneurial effort in developing DNA biosensors for the detection of DNA mutations and DNA binding drug screenings.

Since joining Tulane in February, Li has worked with Tony Hu, PhD, the Weatherhead Presidential Chair in Biotechnology Innovation, and his lab to develop advanced diagnostics for infectious diseases including COVID and tuberculosis.

The caliber of this years class of NAI Fellows is outstanding. Each of these individuals are highly-regarded in their respective fields, said Dr. Paul R. Sanberg, FNAI, President of the NAI. The breadth and scope of their discovery is truly staggering. Im excited not only see their work continue, but also to see their knowledge influence a new era of science, technology, and innovation worldwide.

The 2021 Fellow class hails from 116 research universities and governmental and non-profit research institutes worldwide. They collectively hold over 4,800 issued U.S. patents. Among the new class of Fellows are 33 members of the National Academies of Sciences, Engineering, and Medicine, and three Nobel Laureates, as well as other honors and distinctions. Their collective body of research and entrepreneurship covers a broad range of scientific disciplines involved with technology transfer of their inventions for the benefit of society.

To date, NAI Fellows hold more than 48,000 issued U.S. patents, which have generated over 13,000 licensed technologies and companies, and created more than one million jobs. In addition, over $3 trillion in revenue has been generated based on NAI Fellow discoveries.

The National Academy of Inventors is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. It was founded in 2010 to recognize and encourage inventors with patents issued from the United States Patent and Trademark Office, enhance the visibility of academic technology and innovation, encourage the disclosure of intellectual property, educate, and mentor innovative students, and translate the inventions of its members to benefit society.

Originally posted here:
Tulane Professor Elected to National Academy of Inventors - bizneworleans.com

Webinar The Role of Critical Minerals in Clean Energy Transitions, 13 May 2022 – ThinkGeoEnergy

Join this webinar with Dr Datu Buyung Agusdinata, from the Arizona State University, for an interesting presentation on "The Role of Critical Minerals in Clean Energy Transitions".

The ASU BILGI Talk Series will be hosting world-renowned intellectuals and researchers contributing to our understanding of the complex range of forces which are reshaping our world. The series will be global in nature, crossing the boundaries between cultures and disciplines.

On Friday, May 13, 2022, Senior Global Futures Scientist Dr. Datu Buyung Agusdinata will be the guest. Deputy Chair, Department of Energy Systems Engineering in Istanbul Bilgi University Fusun Servin Tut Haklidir will be the moderator.

(Datu) Buyung Agusdinata was an associate research scientist at Purdue University before joining the Northern Illinois University as a faculty member. His main research interests include sustainable energy and transportation systems, green supply chain, system analysis of the development and impacts of nanomedicine, and drought adaptation policies.

As a guest faculty researcher at the Argonne National Laboratory, he investigated the added values of improved forecast of electricity generation from solar to support a better integration of solar energy to the electricity market. Recently, he serves as a co-PI on an NSF-funded workshop to identify climate change mitigation strategies based on improved understanding and management of coupled food, energy and water (FEW) production-consumption systems.

Click here to register in advance for this webinar.

Source: Istanbul Bilgi University via our Turkish language platform JeotermalHaberler

See original here:
Webinar The Role of Critical Minerals in Clean Energy Transitions, 13 May 2022 - ThinkGeoEnergy

Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Satellite Bio emerged from stealth today to reveal first-in-kind Tissue Therapeutics, bioengineered tissues that repair, restore or replace critical organ or tissue function.

Satellite Bio has raised $110 million in previously undisclosed Seed and Series A investments. The Series A round was led by aMoon Growth, and included prior seed stage co-lead Lightspeed, aMoon Velocity, Polaris Partners and Polaris Innovation Fund. New Series A investors included Section 32, Catalio Capital Management and Waterman Ventures.

Through the exclusive Satellite Adaptive Tissue (SAT) platform, Satellite Bio selectively programs cells and then assembles them into novel, implantable therapies, called Satellites, which can be introduced to patients to repair, restore or even replace dysfunctional or diseased tissue or organs. Satellites enable full cell function in vivo, overcoming many of the challenges that have hindered prior attempts to restore organ function and change the course of progressive and difficult-to-treat diseases.

Tissue Therapeutics replaces organ and tissue systems that break down during disease progression. This next frontier of regenerative medicine has enormous potential to provide solutions for some of the most elusive diseases, said Dave Lennon, PhD, chief executive officer of Satellite Bio. Our SAT platform can be used with virtually any type of cell across a wide range of clinical applications, enabling the potential to create a broad pipeline of implantable Tissue Therapeutic solutions for patients.

Satellite Bio has an exclusive license to technology originating in the labs of Sangeeta Bhatia, MD, PhD, director, Center for Nanomedicine, Massachusetts Institute of Technology and Christopher Chen, MD, PhD, director, Biological Design Center, Boston University. Building on the work of Dr. Robert Langer and others, they combined more than two decades of collaborative research in tissue technology, biology and bioengineering to create this new class of regenerative medicine called Tissue Therapeutics. The company was founded by Bhatia and Chen, along with Arnav Chhabra, PhD, head, Satellite Bio Platform R&D in Cambridge, MA, in 2020.

Satellite Bio is led by Dave Lennon, PhD, CEO, who most recently served as president of AveXis and Novartis Gene Therapies, where he launched the groundbreaking regenerative medicine Zolgensma, a gene therapy for spinal muscular atrophy. Satellite Bio is also announcing the appointments of Laura Lande-Diner, PhD, chief business officer and Tom Lowery, PhD, chief technology officer to the executive team. Joining Dave and the Satellite Bio team is an experienced and diverse group of advisors and directors.

"aMoon is proud of our continued partnership with Satellite Bio on its inspiring mission to restore hope to patients suffering from severe, life-threatening conditions, said Dr. Yair Schindel, co-founder and managing partner, aMoon Fund. This new wave of Tissue Therapeutics will save patients whose only other hope would be organ transplant or experimental therapies.

About Tissue Therapeutics

Tissue Therapeutics is a new type of regenerative medicine that programs cells and assembles them into Satellites. They can be implanted into patients to restore, repair or replace dysfunctional or diseased tissue or organs away from the affected organ. These Satellites provide the full repertoire of cell function in vivo and provide an entirely new way to restore organ dysfunction and change the course of elusive, life-threatening diseases.

About Our Leadership

Satellite Bio is led by Dave Lennon, PhD, who most recently served as president of AveXis and Novartis Gene Therapies, Lennon also serves as a board member for the Alliance of Regenerative Medicine (ARM). He is joined on the Satellite Bio board and management by a diverse group of experienced investors and leaders, including Chief Business Officer Laura Lande-Diner, PhD, and Chief Technology Officer Tom Lowery, PhD. Lande-Diner, a scientist, innovator and life sciences entrepreneur, brings deep expertise in company creation and early operationalization across technologies and therapeutic areas. Prior to joining Satellite Bio, she was part of the Flagship Pioneering ecosystem where she was on the founding teams of Valo Health, Omega Therapeutics, Inari Agriculture and Epiva/Evelo Biosciences. Lowery brings 15 years of deep experience in product, process and analytical development and engineering, as well as building highly productive technical and operational teams. He was previously chief scientific officer of T2 Biosystems, where he led technology development from inception through regulatory approval and commercialization for seven products.

About Satellite Bio

Satellite Bio is on a journey to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine.

With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases.

Satellite Bios quest is as audacious as it is clear: bring new hope to patients and families suffering from elusive diseases. Tissue Therapeutics is how it will deliver on that promiseand why it is deeply committed to leading and realizing the potential of this exciting new frontier in regenerative medicine. For more information, visit satellite.bio.

See the original post here:
Satellite Bio Reveals Pioneering Tissue Therapeutics, Bioengineered Tissues That Restore Organ Function, Bringing Hope Across Diseases - Business Wire

The Top 10 Technology and Business Trends of 2022 – Inc.

As Covid-19 vaccinations increase globally, life is getting back to normal. However, it's no longer the world we experienced before the pandemic. The long-term nature of this global crisis has changed customer needs and daily lifestyles. This will, in turn, change what I expect the world to look like in 2022 and beyond. Let's review the top 10 technology and business trends that we'll likely encounter in the coming year.

Momentum in Life Science Technologies

The life science industry comprises pharmaceuticals,biotechnology, environmental sciences, biomedicine, nutraceuticals, neuroscience, cell biology, and biophysics. Partially because ofincreased investments in mRNA vaccine technology and high-performance Covid-19 testing, 2021 has driven great innovation in life science technologies.

Examples of this innovation include the mRNA-based vaccines developed by Pfizer-BioNTech and by Moderna. Recent Covid drug developments by Merck have also pushed the life science industry forward rapidly.

Looking ahead, I expect we'll see strong movement in the several life science sectors, including advanced research; application of robotics technology; artificial intelligence (A.I.) tools; use of cloud technology; the improvement of drug testing speed; integration of genetic information; and usage of gene technology. I also foresee the development of personalized medicine through advancements in genetics technology. The startup 23andMe, for example, helps people access, understand, and benefit from the human genome.

Networking and Interconnectivity: Expansion of 5G-6G and Satellite-Based Internet Usage

As remote working becomes commonplace, internet reliability becomes more vital than ever. The internet of things (IoT) makes the internet a more integral part of our lives, and developments at all network levels will continue to drive research and push the internet economy forward.

According to Cisco's Visual Networking Indexforecast update for 2018, there will be 1.4 billion more people using the internet by 2022, compared with 3.4 billion users in 2017. This equates to almost 60 percentof the global population, assuming a population of eight billion by 2022. By then, internet users are expected to consume 4.8 zettabytes of data per year, 11 times the amount of IP traffic generated in 2012, with 437 exabytes.

While 5G may be in its infancy, we'll see an increased focus on 6G in 2022. China started research into 6G in 2018. By late 2020, the country had launched a satellite to test terahertz signal transmission. Huawei and ZTE were involved. The U.S. also started 6G research in 2018 with the Federal Communications Commission (FCC) opening higher frequency spectrum for experimental use. A Next G Alliance was started in 2020, with companies on board including Apple, AT&T, and Google. Korea, Japan, and some European countries have started looking into 6G seriously, and we expect to see more announcements in 2022.

High-Performance Computing Becomes Mainstream

Given the recent growth of big data-based research and analysis and cloud-based computing, I expect high-performance computing usage to surge in 2022. From drug discovery to cancer research to space exploration, high-performance computing will become increasingly important, and quantum computing technology needs to keep up with business demand.

We've already seen massive development in quantum computing space by players including Google, IBM, Microsoft, Amazon, and Alibaba. Startups such as Rigetti Computing, D-Wave Systems, ColdQuanta,1QBit, Zapata Computing, and QC Ware have exceeded the industry expectations in their technology and their growth.

I expect rapid progress in quantum computing during 2022, because the high demand for larger machine power is going to accelerate development in this sector.We'll likely see announcements of large qubit developments in the new year. Commercial quantum computing will soon be within our reach, and new breakthroughs will occur at an accelerated pace.

Continued Growth in Artificial Intelligence, Big Data Analytics, and Cloud Computing

A.I. has become an integral part of our lives. From improvements to personalization, ranking search results, recommending products, and understandingand controlling devices tobuilding better models of the environment to automatingindustry, we see the application of artificial intelligence everywhere as we look toward 2022.

Organizations are using predictive analytics to forecast future trends. According to a report published by Facts & Factors, the global predictive analytics market is growing at a compound average growth rate of around 24.5 percentand is expected to reach $22.1 billion by the end of 2026.

We will also see massive growth in cloud computing. By 2022, the cloud will be more entrenched and more computing workloads will run on the cloud. The internet of things will push this space in a bigger way, for sure. According to predictions from Gartner, global spending on cloud services is expected to reach over $482 billion in 2022, up from $314 billion in 2020.

Internet Security and Privacy Dominate

As the world becomes more digital, we're seeing an increased number of personal and organizational cyberattacks around the world. Several corporations have been the target of major cyberattacks in recent days, and businesses have become more vulnerable to destructive attacks, in part because ofincreased remote work giventhe pandemic.

During 2022, I expect that we'll see cyberattacks across sectors, and we will see the industry take a variety of counteractive measures. Defending against cyberattacks will include educating individuals so they can identify and avoid network assaults, thereby safeguarding their company's image.

Applying A.I. will make robust cybersecurity protocols easier andless expensive to createand more effective than ever. Use of A.I. can enable cybersecurity to spot risks and learn the behaviors of cybercriminals, thus preventing prevent future attacks. It can also help cut down on the time it takes cybersecurity specialists to do their daily tasks.

The MetaverseWill Shine in 2022

The metaverse is a digital reality combining social media, online gaming, augmented reality, virtual reality, and cryptocurrencies to allow virtual user interaction. The metaverse may refer to anything on the internet, including all of AR's offerings. Virtual space of the future describes the metaverse, providing access to all kinds of entertainment and projects, including the opportunity to work.

We expect the metaverse to be immersive, ubiquitous, and free to access. It will be digitally focused, and potentially involves entertainment, social connection, work productivity, and behavior modification at scale. It will create an entire ecosystem for developers, apps, ads, and new digital innovations. The metaverse will facilitate convenience, consumption, and a frictionless access to services.

Only a few companies today have a real stake in the metaverse. They include ByteDance, Tencent, Facebook, Spotify, Zoom, Amazon (Twitch), Alibaba, Roblox, Bilibili, Snapchat, Kuaishou, and Huawei. Apple's wearables also point to the metaverse with AR glasses coming soon. Microsoft with Microsoft Teams and gaming is perhaps the most advanced company in the world regarding the metaverse. WeChat's ability to facilitate payments and access to a variety of services is the start of the metaversesuper apps.

As the metaverse ecosystem grows in 2022, I expect it will have a direct impact on the future of many technology sectors. These include gaming, wearables, VR and AR, collaborative productivity (Canva, Slack), consumer tech products (including AR glasses or smart speakers), social networks, educational technology, health technology, communication technology (Zoom), digital currencies, and convenience mobilization and on-demand consumption (Amazon, Meituan, Alibaba, JD.com, Shopify).

NFT Platforms Will Boom

A non-fungible token (NFT) is a digital object: computer code and data that conveys ownership of something. The property may be online:for example, virtual real estate in the digital world or special equipment in a video game. Or it could be real: real estate, a painting, or a seat at a concert. An NFT can also be a hybrid:for example, the right to decide who can rent a room in a cooperative living space. A baseball card, Ronaldo's first ball, a vintage car, or a piece of land in Central London: All are one of a kind and can be transferred to the NFT.

In 2022, we are likely to see NFTs everywhere; this includes in movies, TV shows, books, and more. NFTs are part of the digital economy and are becoming mainstream because they allow people to own something that represents a part of something bigger than themselves -- a piece of art or a character, for example. The digital economy is made up of a variety of online markets, including game economies, virtual real estate, and even social media platforms like Facebook.

Our society has changed rapidly over the past decade, especially because of the 2008 to 2009 economic crisis and the pandemic. These trends are coming together to shape a world where NFTs will beat traditional collectibles, making 2022 a tremendous year.

The Robotics Sector Will Become More Prevalent

We expect to see an increased use of robotics in everyday life during 2022. Usage will include the health care, agriculture, automotive, warehousing, and supply chain management sectors, and we will see more robotics-based automation that will continue to progress.

The Covid-19 pandemic presents both problems and opportunities forroboticscompanies in the logistics and supermarket industries. Unexpected strains on supply systems and product shortages have highlighted the need for better supply chain efficiency. It's also become obvious thatrobotsand automation providea safe means for manufacturers to keep employees socially separated yet allow the business to continue operating.

The use of robotics process automation (RPA) helps automate activities that are performed repeatedly; we expect RPA to grow in 2022 and become a standard technology for business. CIO reports that chief information officers are using RPA to free workers from boring, repetitive tasks and allow them to do more fulfilling work. Finally, we're seeing a rise in nanorobotics, tiny sensors with limited processing power. The first useful applications of these nano-machines may be in nanomedicine. Biological machines, for example, are used to identify and destroy cancer cells or deliver drugs.

Increased Urgency in the Renewable Energy Technology Sector

Climate change and dramatic news headlines are driving rapid growth in sustainable energy adoption. During the pandemic, this has been the only energy sector that has grown. According to the International Energy Agency (IEA), 40 percentmore green energy was generated and used in 2020; the agency expects continued growth in 2022. The falling costof generating sustainable energy also helps ensure that mass adoption is likely. While newer energy technologies like nuclear fusion, biofuel, and liquid hydrogen might take longer to come full circle, we look forward to serious advancements in 2022.

I also expect to see massive growth in the production and usage of solar and wind technology. Storage (battery) technologies are playing a larger role, since there will be an increased need to store renewable energy.

Blockchain Technology Prevails

Blockchain, an innovative breed of distributed ledger, enables companies to track a transaction and do business with unverified parties -- even without the assistance of financial institutions. This new capability significantly lessens business conflicts; it also adds other benefits such as append-only data structure, transparency, security, immutability, and decentralization.

Blockchain technology has enjoyed massive adoption and continues to disrupt many industries, from gaming and governance to finance. According to the International Data Corporation, companies will spend almost $6.6 billion on blockchain solutions in 2021, a 50 percentincreasefrom the previous year. This number is expected to grow beyond $15 billion in 2024. With the new rise of NFTs and themetaverse, blockchain will become more important in 2022.

Businesses are encouraged to start studying blockchain technology, since it is expected to generate significant business opportunities; Statista reports that global blockchain technology is predicted to grow to more than $23.3 billion by 2023. A notable existing blockchain deployment is that of Walmart's supply chain database application, allowing the monitoring of individual products directly to their very source, effectively elevating food supply standards. Amazon is rolling out its blockchain initiatives for 2019, which allow its Amazon Web Services clients to benefit from distributed ledger solutions.

Looking Ahead

There's little doubt that 2022 will see rapid progress in these and other technologies, as the world emerges from the Covid-19 pandemic. I see a prime opportunity for smart startups, corporations, and investors to capitalize on these emerging technology and business trends to become more successful than ever. Let's hope that the resulting innovation makes the world better for people and businesses.

The opinions expressed here by Inc.com columnists are their own, not those of Inc.com.

Read more here:
The Top 10 Technology and Business Trends of 2022 - Inc.

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully…

DGAP-News: MagForce AG / Key word(s): Study20.12.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

Berlin, Germany and Nevada, USA, December 20, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc., announced today that enrollment of patients in Stage 2b of its pivotal U.S. study with the NanoTherm therapy system for the focal ablation of intermediate risk prostate cancer is successfully proceeding.

Following FDA approval to initiate Stage 2b with the final study protocol in November, MagForce USA, Inc. has since received the green light from the ethics commission ("Institutional Review Board", IRB) to proceed with the study at the respective centers. After IRB approval, MagForce has now enrolled the first patients into the clinical trial while continuing to reach out to pre-identified potential study participants for updated testing and preparations. Up to 100 men diagnosed with intermediate risk prostate cancer that has progressed to a stage where a clinical review and treatment change is required will be enrolled at the NanoTherm treatment centers owned and operated by MagForce.

"We are happy that enrollment in Stage 2b of our pivotal US study has successfully commenced and that the recruitment process is progressing well, despite once again surging Covid-19 cases. Stage 2b builds on the positive findings of earlier studies which demonstrated safety and efficacy of our approach and importantly, showed no treatment-related side effects frequently experienced with other therapies, such as sexual, urinary or gastrointestinal dysfunction or loss of energy. We are excited about the trials' potential results and are hopeful to be able to provide prostate cancer patients with a minimally invasive and highly accurate treatment option," said Ben Lipps, CEO of MagForce AG and MagForce USA, Inc.

Stage 2b of the single-arm pivotal study is planned to evaluate the use of NanoTherm ablation for the treatment of prostate cancer patients with intermediate grade lesions and confirm the favorable results seen in Stage 2a in a larger patient population. The trial is designed to demonstrate that the NanoTherm therapy system can focally ablate targeted prostate cancer lesions with minimal side effects. Subsequently the patients should then be able to return to active surveillance without definitive treatment, such as external beam radiation or prostatectomy.

MagForce previously reported encouraging findings from Stage 1 and 2a of its pivotal study confirming a highly favorable safety and tolerability profile. Treatment with the NanoTherm therapy system showed no unanticipated serious adverse events but only minimal treatment-related side effects, which were tolerable and similar to those commonly associated with biopsies.

Based on the current plan and conditions set out by the FDA, the clinical trial is expected to be finished in summer 2022. Following the final protocol, MagForce will submit interim data packages at 15 and 30 patients treated for FDA review, whilst treatments continue, which will be updated and submitted for approval after trial completion.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.com Get to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contact:MagForce AG, Max-Planck-Strasse 3, 12489 BerlinBarbara von Frankenberg,VP Communications & Investor RelationsP +49-30-308380-77M bfrankenberg@magforce.com

20.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at http://www.dgap.de

View post:
MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully...

Challenges and Successes of Dealing with COVID-19 in India | RRTM – Dove Medical Press

Introduction

The World Health Organization (WHO) affirmed COVID-19 as a pandemic on 11 March 2020 but earlier to this the Chinese government confirmed the first outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan on 31December 2019. The state-wise lockdown, which was imposed in India due to the second wave of the novel coronavirus pandemic, affected people belonging to every economic stratum. In India, till now (9 July 2021), there have been 30,752,950 confirmed cases of COVID-19 with 405,939 deaths reported to the WHO. COVID-19 cases are rapidly rising globally of which the first case was registered on 21February 2020 in Italy. Meanwhile in India, case numbers have risen, and community transmission was officially declared by government in October 2020. Life is deeply affected by COVID-19 even for the ones who are not infected as isolation, contact restrictions and economic shutdown have changed the social and economic scenario of India. Vast populations and crowded settlements have increased the number of cases in China, Europe, USA and India. Countries with dense populations and robust travel history will increase the problem of decision-making authorities if testing is limited or disproportionate. The WHO has made projections of 3.5 beds per 1000 population1 but many countries have only 1.3 beds per 1000 population in hospitals which is again the concern of government. As the pandemic is growing in stages, this review assesses the prospects these stages might have on the Indian population as it highlights some key challenges for treatment and research related to antiviral drugs.

Cases were initially spread by migrants, overseas visitors, and some others who were in contact with these infected persons, and to control this spread lockdowns were called by various countries including India. The situation seemed to be under control due to the lockdown, but due to a religious gathering in New Delhi, which led to the human-to-human transmission of COVID-19, a sudden horrific increase in COVID-19 cases occurred. Initially, most individuals who came into contact with such infected individuals were unaware of the effects of the virus in their bodies. To sustain the countrys economy, unlocks were called by the Indian Government in multiple phases, therefore, the persons who were unaware that they were carrying the virus spread it many more healthy persons. However, preventive measures including social distancing, quarantine and isolation techniques had been taken globally and have proven effective in the absence of drug treatments and other approaches. Adults (ages 50 and over), and people with comorbidities can have higher chances of becoming severely ill with COVID-19 and contribute to the largest portion of all deaths worldwide among infected cases.2,3

In India, the overall numbers dying constantly increased, amongst them a lot of the demise circumstances pointed to a particular age-group of aged folks.4 In India, among the total COVID-19 cases (30,752,950) and total deaths (405,939) till 9 July 2021, 90% were older than 40 years. Overall, people in the age group of 40 years and greater, have suffered the major impact of the current COVID-19 eruption and are more vulnerable.5,6 The massive loss of people in the workforce is likely to have devastating social and economic consequences.

The basic measures adopted worldwide include maintenance of hand hygiene, avoiding close contact, using face masks, disinfection and monitoring health.7 The ongoing COVID-19 pandemic has once again brought the benefits of appropriate hand hygiene (hand washing and use of alcohol-based hand-sanitizers) to the centre stage. Since hand washing is not a feasible and available option at all times, the use of alcohol-based hand-sanitizers (hand rubs) has been recommended by health organizations, when hands are not visibly soiled. These sanitizers act as a powerful, fast acting and effective solution with broad antimicrobial range.7 Hands act as a medium for exchange of microbes between the organism and its environment. The skin of the hands harbours a variety of organisms ranging from commensal to potential pathogens. Therefore, adequate hand hygiene can greatly reduce disease transmission. The most commonly used agents for hand disinfection are hand-sanitizers. There are two major types of preparations available: alcohol-based and alcohol-free. The alcohol-based ones, known as alcohol-based hand rubs (ABHRs), typically have ethyl alcohol (ethanol), isopropanol, or n-propanol at concentrations between 60 to 95% alcohol.8 The alcohol-free preparations usually contain quaternary ammonium compounds (benzalkonium chloride or benzethonium chloride). However, these have been found to be less effective and have a risk of contributing to antimicrobial resistance (AMR), hence are not recommended by CDC.

The CDC has recommended the use of ABHRs and hand washing to fight the COVID-19 pandemic. This is due to the structural characteristics of coronaviruses, which are enveloped viruses with lipid bilayer and are easily inactivated by alcohol. A combination of factors such as inappropriate formulations, excessive/repeated usage of hand sanitizers during this pandemic will have far reaching consequences. These may range from emergence of situation like alcohol tolerance and antimicrobial resistance (AMR), disturbance of normal microflora, and product toxicity. Similar to antibiotics, excessive or repetitive application of alcohol through hand-sanitizers has the potential to act as a selection pressure for the emergence of new microbial species tolerant to high alcohol concentrations.9

Taking note of the repetitive use of ABHRs, Professor Tim Stinear from the Peter Doherty Institute for Infection and Immunity remarked

Anywhere we repeat a procedure over and over again, whether its in a hospital or at home or anywhere else, youre giving bacteria an opportunity to adapt, because thats what they do, they mutate. The ones that survive the new environment better then go on to thrive.

He further added that the risk increases when appropriate guidelines are not followed.10

Eliminating the normal microflora of the skin by repeated use of hand-sanitizers may eventually deprive the skin of the protection offered by these commensals. Long term use of personal protective equipment along with frequent hand hygiene was responsible for high rate of skin damage in 97% of respondents while frequent hand hygiene was attributed with increased risk of hand skin damage.11

The world has joined hands with parallel efforts for the production of vaccines in opposition to COVID-19 pandemic.

A densely populated area like Ladakh has set an example for implementation in the Guidelines for hygiene and sanitation during the era of COVID-19 pandemic by setting up Foot-Operated Washing Station, implemented at the Indian Astronomical Observatory (IAO), Hanle. Having one of the worlds highest located sites for optical, infrared and gamma-ray telescopes operated by the Indian Institute of Astrophysics (IIA), Bengaluru, IAO12 has one in all the worlds highest set sites for optical, infrared and gamma-ray telescopes.

Antiviral nano-coating and new nano-based material for use in Personal Protective Equipment (PPE) was invited by The Department of Science and Technology (DST) using the Science and Engineering Research Board (SERB) portal, scale up for which could be done by partnering industry or start-up. India could be supported greatly by such nano-coatings technology to fight against COVID-19 pandemic. N-95 respirator, PPEs kits and triple-layer medical masks could be prepared from antiviral nano-coatings for safeguarding healthcare workers.13

Patients that showed flu-like symptoms was screened and detected for COVID-19 through indigenous company Mylab Discovery Solutions through the development of PCR-based molecular diagnostic kit.

TDB will try to boost the production process of kits so that present capacity could increase from 30,000 tests per day to one lakh tests per day. This automation by company could be achieved within the next few months. Considering the national emergency COVID-19 kit will be deployed by ICMR and CDSCO.14

As the demand increased, production of sanitizers have seen a boom amid coronavirus outbreak. Owing to which alcohol-based herbal sanitizer was developed by NBRI under Council of Scientific and Industrial Research (CSIR)-Aroma Mission as per the World Health Organisation (WHO) guidelines. Apart from having 60% of isopropyl alcohol for killing germs it has essential oil from Tulsi as natural antimicrobial agent. It is not only last for 25 minutes but also prevents skin from dehydrating. Herbal sanitizer has been found to be effective against the pathogen (Staphylococcus epidermidis).15

The Council of Scientific and Industrial Research (CSIR) is leaving no stone unturned in the battle against novel coronavirus. Repurposing of existing drugs is one of the strategies deployed by CSIR. The Council is implementing this strategy by evaluating an existing drug (Sepsivac, that available commercially) that is used for treating gram-negative sepsis patients. Both Gram-negative sepsis patients and critically ill COVID-19 patients, exhibit the altered immune response and a massive change in the cytokine profiles. Cytokines are produced in response to an infection and they are essential for host defence against pathogens. There are six types of cytokines, which belong to different families and the mixtures of cytokines, called cytokine profiles. One of the significant contributors to death by COVID-19, has shown the heightened immune response, called a cytokine storm. The immune system starts attacking both infected as well as uninfected cells and unable to discriminate between a friend and a foe, leading to tissue damage which resulting in sepsis. This drug (Sepsivac) modulates the immune system of the body and thereby inhibits the cytokine storm leading to reduced mortality and faster recovery.16

ICMR releases advisory for use of Cartridge-based Nucleic Acid Amplification Test (CBNAAT) using Cepheid Xpert Xpress SARS-CoV-2, effective from 19 April 2020.17

Indias first antibody-based testing kit was developed by NuLife Consultants and Distributors Pvt. Ltd, New Delhi which takes only fifteen minutes to yield accurate results. It is launched in two weeks and regular production has also started it was approved by the Indian Council of Medical Research (ICMR).18 The new finger prick kit will provide adequate access to cost-effective testing.

Home screening test kit for COVID-19 was launched by Bione with easy-to-use kit displays after approval from the requisite medical regulatory authorities.

In a get through development, the Company has devised the screening kit which can provide respite from the impending fear of the contagion. It will foster timely detection of the disease while acting as a preventive tool for others in proximity to the user, by isolating the carrier immediately. The kit is priced between `20003000 depending upon the global supply, to increase its affordability for the masses. Under normal circumstances, the ready-to-use kits can be received within 23 days of placing the order at their platform. To initiate an effective screening tool for mass screening, the organisation is also in talks to provide bulk orders for early detection.19

Against COVID-19 drugs and experimental molecule are being prepared. SARS-CoV-2 is a single stranded RNA enveloped virus. The angiotensin-converting enzyme 2 (ACE2) receptor of the host cell binds to the spike (S) protein of the viral structure. The host type 2 transmembrane serine protease, TMPRSS2 facilitates the S protein.20 Once the virus enters the host, it starts synthesizing RNA through its RNA dependent RNA polymerase enzyme, which is then translated to products. Structural proteins facilitate the assembly and release of viral particles.21,22

During viral life cycle, chemotherapy is available of various potential targets. There are many non-structural protein promising drug targets which resembles with other coronaviruses (SARS-CoV and MERS-CoV) such as 3-chymotrypsin like protease, papain like protease and RNA-dependent RNA polymerase. Various molecules and their targets are represented in Figure 1.

Figure 1 Mechanism of various drugs/molecules on COVID-19 disease.

Chloroquine and hydroxychloroquine used in prevention and treatment of malaria and chronic inflammatory diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).23 CQ and HCQ are reliable anti-malarial drugs approved by FDA, which shows positive response against SARS-CoV-2 infections and hence used for the treatment of COVID-19 patients by clinicians.2426 It inhibits the entry of the virus by either altering the configuration of structure of cell receptors or by compete to bind with cellular receptors.27 The glycosylation of ACE-2 cellular receptors can amend by CQ/HCQ which is needed for entry of SARS-CoV-2. Apart from that CQ/HCQ can also prevent the attachment of SARS-CoV-2 to the host cells by decrease the synthesis of sialic acid.

The binding affinity of these drugs is better as compared to the S protein of SARS-CoV-2. Therefore it prevents attachment and entry of virus because of competitive binding of sialic acid and gangliosides present on surface pf target cell.28

In addition to the antiviral activity of CQ/HCQ, they have anti-inflammatory activity that may contribute to its efficacy in treating COVID-19 patients. Through the attenuation of cytokine production, these drugs also have immunomodulatory effects and inhibition of lysosomal and autophagy activity in host cells.24,29 In vitro activity of HCQ with lower EC50 for SARS-CoV-2 as compared to CQ after the growth of 24 hours (HCQ: EC50=6.14 M and CQ: EC50=23.90 M).30

A study from China reported which results in improved radiologic findings, enhanced viral clearance, and reduced disease progression by treating successfully with CQ on 100 COVID-19 cases.31 When treatment given to 6 patients, then it is observed that as compared to HCQ monotherapy (8/14, 57%) the combination of azithromycin with HCQ (6/6, 100%) results in numerically superior viral clearance.32

Other than these positive results, this study has many limitations like intolerance of medication, different viral loads between HQC combination and monotherapy and no safety outcomes are reported.

Another study of 30 patients in China shows there was no difference in virologic outcomes to HCQ plus standard of care (supportive care, interferon, and other antivirals). At 7th day virologic clearance was similar with clearance for the HCQ plus standard of care group and standard care group ie 86.7% vs 93.3% respectively, (P>.05).33 Currently, for COVID-19 treatment several RCTs of both CQ and HCQ examining their roles. To treat COVID 19 500 mg dose of CQ orally once or twice daily is advised.8,9

However, there is shortage of data regarding the optical dose to ensure efficiency of CQ For HCQ, daily dose of 400 mg taken orally is recommended.34

Both the agents are well tolerated by patients with SLE and malaria as demonstrated by their experiences and they can cause rare and serious adverse effect (>10%) such as hypoglycemia, neuropsychiatric effects, and retinopathy.

Lopinavir/ritonavir is FDA approved for treating HIV and it shows in vitro activity against coronavirus by inhibiting 3-chymotrypsin like protease.35 The therapy during early peak viral replication phase (initial 710 days) is important because delayed medication with lopinavir/ritonavir had no effective outcomes.36,37

Although many RCTs of lopinavir/ritonavir examine their role, limited role for lopinavir/ritonavir in COVID-19 treatment is suggested through current data.38

Recent RCT shows that approximately 50% of patients experienced an adverse effect under the lopinavir/ritonavir therapy and 14% of patients stop therapy due to adverse effects on gastrointestinal region. In several COVID-19 investigational trials, alanine transaminase elevations are exclusion criterion. Hepatotoxicity induced by lopinavir/ritonavir could limit patients ability to access these drugs.39

The activity of darunavir is demonstrated in vitro cell models against SARS-CoV-2. With these drugs there is no clinical data is available in COVID 19, but in China RCT of darunavir/cobicistat is going on.40,41 Ribavirin is a analogue to guanine which inhibits viral RNA-dependent RNA polymerase and used as best candidate for treatment of COVID 19.

However, it has limited in vitro activity against SARS-CoV and high doses is required to prevent viral replication (e.g., 1.2 g to 2.4 g orally every 8 hours) and combination therapy. For nCoV treatment no evidence exists for inhaled ribavirin..42 Generally ribavirin is used in combination with interferons in the treatment of MERS, no visible effect is shown on clinical outcomes. A lack of clinical data with ribavirin for treatment of COVID 19, means its therapeutic role must be extrapolated from other nCoV data.43,44 The high doses used during trials SARS resulted in hematologic toxicity and hemolytic anemia in more than 60% of patients. Similar safety concerns were seen in MERS trial, with 40% of patients taking ribavirin with interferon requiring blood transfusions. 75% of patients experienced transaminase elevations while taking ribavirin for SARS. Ribavirin is a teratogen and prescribed as not to be used pregnancy.45,46

It is a nucleoside reverse - transcriptase inhibitor that is worthy in clinical trial against COVID-19. It acts as an inhibitor of RNA-dependent RNA polymerase (RdRp)47 and in SARS-CoV and MERS-CoV infections its pharmacokinetics and characteristics have been studied.48 It inhibits the viral genomic replication and production by disturbed reading due to alteration in the function of viral exonuclease.49

Therefore it can suggested for COVID 19 patients to prevent severity of disease progression such patients are taken to phase 3 trials to check the therapeutic efficiency of remdesivir.50

Favipiravir (T705) is considered as RdRp inhibitor as it is an analog to guanine nucleotide (a derivative of pyrazine carboxamide).51 Initially it was used against influenza but because of its large spectrum antiviral properties, it attracted more attention for treatment of COVID 19.52

An in silico study showed that as compared to lopinavir, atazanavir bound more strongly to the active site of SARS-CoV-2 MPro and an in vitro study found that replication of SARS-CoV-2 inhibited by atazanavir.53

Oseltamivir is used for treatment of influenza because it acts as a neuraminidase inhibitor. It has no data against SARS-CoV-2. Initially in China during the COVID-19 outbreak until the discovery of SARS-CoV-2 as the cause of COVID-19 a large proportion of patients were treated with oseltamivir therapy because outbreak occurred in influenza season.

Once influenza has been excluded this agent has no role in the management of COVID-19.54 Umifenovir has a unique mechanism of action targeting the S protein interaction and inhibiting membrane fusion of the viral envelope. This agent is approved for treatment of influenza in Russia and China and treatment of COVID 19 patients started on the basis of in vitro data which shows its activity against SARS.

A study shows that 67 patients treated with Umifenovir for 9 days had a lower mortality rate and higher discharge rate compared with the patients who were not treated with this medication. This data cannot proof the efficiency of umifenovir, but for evaluating this agent further RCTs are going on in China.55.

For SARS-CoV-2 interferon- and - have been studied, due to their demonstrating activity against MERS by interferon-. Some interferons are listed as an alternative for combination therapy by Chinese guidelines. Traditionally other agents are used to demonstrate in vitro activity to inhibit SARS-CoV-2, but not limited to baricitinib, dasatinib, and cyclosporine. However it should be seen whether it provide protection for COVID 19 patients or not.56

Nitazoxanide has in vitro antiviral activity against MERS and SARS-CoV-2. It is used traditionally as an antihelminthic agent. More studies are required to check the antiviral activity and immunomodulatory effects of this agent. For treatment option for SARS-CoV-2 nitazoxanide is recommended.57 In Japan camostat mesylate is used for treatment of pancreatitis, it prevents cell entry through the host serine protease, TMPRSS2. For future research this mechanism provides an additional drug target.58

The ACE2 receptor is used by SARS-CoV-2 for entry into the host cell. This discovery has increased questions about whether ACE inhibitors and/or angiotensin receptor blockers may efficiently treat COVID-19 or either worsen disease. There are some conflicts if these provide protective effect to COVID-19 patients. Further research is pending for recommending therapy for patients already taking one of these agents.59,60

One of the main challenges in this pandemic is to develop multiple technology platforms for evaluation of agents/molecules against SARS-CoV-2 as this virus shows similarity with various other (Figure 1) corona viruses and shares similar binding receptors (ACE2) in humans (host).61 SARS-CoV-2 has ss-RNA genome of approximately 30 Kbp size and exhibits approximately 89% nucleotide similarly to SARS-CoV found in Chinese bats.20

For SARS-CoV 2 various technologies are being developed such as nucleic acid, replicating viral vector and non-replicating viral vector. New methods based on nucleic acid can facilitate rapid production because they do not need to be fermented. Experiments are conducted to ensure vaccination of larger population without any reduction in efficacy but also with improved immune response along with low dosages.62,63

As of January 2021, more than 200 vaccine candidates for COVID-19 are being tested. Among these almost 52 vaccines are approved for human trials and many other vaccines are in phases I/II and will soon enter phase III trials. Certain national regulatory authorities have nine authorized COVID-19 vaccines.

It represents a classic strategy for viral vaccinations. Finally, a codon deoptimization technology to attenuate the viruses is employed by Codagenix64 and is testing to develop vaccine against SARS-CoV-2, CodaVax-COVID. The inherent immunogenicity and ability to stimulate toll-like receptors (TLRs) is a major advantage of whole virus vaccines. This is especially an issue for coronavirus vaccines, given the findings of increased infectivity following immunization with live or killed whole virus SARS coronavirus vaccines.65

Subunit vaccines depend on producing immune response against S protein to inhibit its binding with host ACE2 receptor.65 Immunogenic virus-like nanoparticles produced by Novavax are based on recombinant expression of the S-protein66 while subunit vaccine consisted of a trimerized SARS-CoV-2 S-protein is developed by Clover Biopharmaceuticals by using their patented Trimer-Tag technology.67

For development of COVID-19 vaccines several major biotech industries have advanced nucleic acid vaccine platforms. Some modifications and formulation have improved nucleic acid performance in humans. This approach may lead to the first licensed nucleic acid based vaccine for humans.

Developing vaccine against the SARS-CoV-2 can cause distinct challenges. Various proteins of SARS-CoV-2 are used for developing proteins like S protein, N protein, M protein is the initial challenge. Developing a vaccine is a long process, starting from product development to the completion of phase III and clinical trials before marketing which takes several years.

Vaccine against COVID-19, known as CoroFlu is under process and its development and testing is done by Bharat Biotech in collaboration with international virologists and vaccine makers. One-drop COVID-19 nasal vaccine named CoroFlu, it is well tolerated in human trials during phase I and phase II. On the backbone of FluGens flu vaccine, CoroFlu has built a candidate known as M2SR. M2SR induces an immune response against the flu; it is a self-limiting version of the influenza virus. To induce immunity against the coronavirus in new virus, Kawaokas lab is trying to insert the gene sequences from SARS-CoV-2 into M2SR.68

To develop a vaccine for SARS-CoV-2, Zydus Cadila, an innovation-driven global pharmaceutical company, initiated a research program along with multiple teams. By reverse genetics the recombinant measles virus (rMV) is produced. It would express codon optimised proteins of the SARS-CoV-2 and provide long-term neutralising antibodies for protection from infection. The plasmid DNA vaccine, also has wide ranging capabilities in developing and manufacturing different vaccines for unmet needs. This is under supervision of the groups Vaccine Technology Centre in India.69

To develop a lead vaccine candidate for SARS-CoV-2 the Vaccine manufacturer Indian Immunologicals Ltd (IIL) has a research collaboration agreement with Australias Griffith University. As part of the cross-continental collaboration, using the latest codon de-optimisation technology Live Attenuated SARS-CoV-2 vaccine could be developed by scientists from IIL and the Griffith University. with a single dose administration this vaccine is expected to provide long protection with an anticipated safety profile for active immunization.70

Now the SII (Serum Institute of india) is preparing its mass production against the coronavirus, mixing out doses of the Covishield candidate vaccine which is being developed by the University of Oxford and the international biopharma company AstraZeneca. In India stage III clinical trials of Covishield are continuing. In the US, Brazil and South Africa the candidate vaccine is also being tested in various stages. Two million doses of the vaccine candidate has already produced over for use in testing by the SII. Recently SII announced a deal with Codagenix, US-based Biotech Company to help develop a vaccine candidate and it is expected that its trials starts by the end of 2020. Nasal COVID-19 vaccine candidate developed by Codagenix Inc. Dubbed the DX-005, manufacturing by SII has started.

After completing preclinical animal studies the coronavirus vaccine entered phase I clinical trials in the United Kingdom by the end of 2020. Bharat Biotech, a private firm collaborated with Indian Council of Medical Research (ICMR) is developing Covaxin. Covaxin has shown good efficacy is said by task force scientist Dr. Rajni Kant ICMR-COVID-19. Bharat Biotech is approved by The Drugs Controller General of India (DCGI) to perform Phase III clinical trials of Covaxin with certain conditions.

Russias president Vladimir Putin endorsed approval of SPUTNIK V (COVID-19 vaccine) that has not passed rigorous medical tests and could have numerous consequences. The effectiveness of the vaccine in response to providing active acquired immunity against COVID-19 and its possible adverse effects remain unknown. Therefore, the fear of vaccination in this particular case may be justified. However, endorsement of a potentially harmful vaccine will inevitably fuel public fears of other existing and future, properly developed, controlled and safe vaccines. Current level of public acceptability of immunization is already worrying, putting at serious risk the effectiveness of any future anti-SARS-CoV-2 vaccination programs, as it has been pointed out by Cornwall 2 and the French COCONEL Group 3. Independently from each other these groups provide evidence that it is a transatlantic phenomenon. Regardless of the suggested correlations between vaccination hesitancy and specific socioeconomic factors, it is clear that anti-vaccination movements are increasingly influential.71 Moreover, the problem is internationally valid, and the rise in the number of adults openly hesitant about routine childhood vaccination in many Western countries justifies the concern about public participation once the COVID-19 vaccine is available.72

In terms of collective immunity, vaccination effectiveness is based on its mass implementation; this may seriously undermine the efforts to protect societies against COVID-19 in the near future. High levels of COVID-19 vaccine hesitancy are reported even from countries severely affected by the pandemic. Only 49% of American respondents plan to vaccinate when the vaccine becomes available.73

Polish research confirms the strong COVID-19 vaccination hesitancy and its international character which is not directly related to the level of confidence in vaccination safety in general. Results of this Polish study show that 28% of adults would not vaccinate against SARS-CoV-2 if the vaccine became available. Alarmingly, a majority (51%) of the reluctant respondents indicated that their minds would not be changed if given information regarding vaccine safety or efficacy, or if threatened with heavy fines. Significantly fewer respondents (37%) supported COVID-19 vaccinations specifically than supported childhood vaccinations in Poland in general (78% in 2018).74 The vaccine hesitancy for the anticipated COVID-19 vaccine varied from very low (26% China) to very high (43%, Czechia, and 44%, Turkey). Surprisingly, the level of unwillingness to vaccinate against COVID-19 is in most countries much higher than regular vaccination reluctance, which varies between 3% (Egypt) and 55% (Russia). Such high levels of vaccination hesitancy may be detrimental to public health. According to current estimates, the benefits of herd immunity are achievable if 67% of the population is vaccinated.75,76

The most effective vaccination programs in the past effectively eradicated certain deadly diseases, such as smallpox which was achieved by combining the mandatory preventive vaccination programs with coordinated education efforts.77 Coronaviruses mortality rate is the highest among elders and people with comorbidities or conditions that affect their immune system. Some occupations have been identified as being the riskiest in terms of contracting COVID-19 such as health-care workers (dental hygienists, family practitioners, and nurses), transportation personnel (flying attendants, and school bus drivers), kindergarten, school teachers, fire fighters and restaurant personnel.78 Highest risk of death and highest risk of contraction should constitute the main criteria for mandatory vaccination. Mandatory vaccination will definitely trigger massive opposition especially bearing in mind the massive protests against social distancing measures and face masks. Focusing at the beginning only on some groups with transparent justification may help weaken the opposition to it.79

The high share of the population unwilling to vaccinate along with the number of people who are unable to receive the COVID-19 vaccine due to certain medical reasons suggests herd immunity may be out of reach. Information about the high death tolls and hospital overflows from the COVID-19 pandemic has recently flooded onto online media, but has apparently not convinced much of the worlds population to plan to be vaccinated. If the disturbing images being streamed live on social media cannot convince a fair share of the population to protect themselves from lethal risk, then educational or social campaigns may be limited in their effect. Educational efforts would be further undermined by the lack of trust in public authority figures, which fuels conspiracy theories and validates medical fake news. In this focused review we have discussed the challenges and opportunities faced during the management of COVID-19 in India.

Health-care systems across developed and developing nations are under tremendous pressure. The majority of this responsibility is being shouldered by frontline health-care workers to limit the spread of the novel coronavirus. They put their lives on the line in order to do so. Here we highlight some challenges faced by frontline HCW and propose certain recommendations to reduce the burden.

The exposure to the virus causes severe illness and mortality to a significant extent and also leads to physical and psychological exhaustion. This pandemic leads to health departments calling retired and experienced medical staff and clinical scientist back to work. Deficient supplies of personal protective equipment (PPEs) and other vital necessities is reported in various news channels all over the world. Majorly WHCs are affected and they are working in the emergency, they need PPEs and other vital necessities most.

In this pandemic, battling endless hours, staff shortages and deficient supplies, most are isolated from their families, affecting them physically, mentally, and emotionally, which will increase the morbidity and ill health.80 These mental health problems will not only affect decision making ability, judgement and attention of HCWs, but also affect the understanding the disease and have a long-lasting impact on their overall well-being.80

A few recommendations are proposed which are listed from all the information received around this issue.

Health-care staff/HCWs are also the most important resource as hospitals, equipments and PPEs in this pandemic situation. Post Traumatic Stress Disorder is reported in many health-care workers who have no time to protect themselves as well as their families. If any staff gets infected then they should be quarantined themselves, which leads to a shortage of staff and then healthy workers are stretched further for endless duties with lack of sleep and anxiety. For frontline health workers testing kits must be prioritized, as well as for weak communities (senior citizens) more susceptible to the virus and those who have many pre-existing diseases.81,82

Health-care workers face a high risk of getting infected as they take care of patients who are already infected. Protective clothing, sufficient hand sanitizers, washing paraphernalia and head covers are essential commodities which have to be provided to them in sufficient amount. Along with providing PPEs in adequate amount, its disposal methodology is also an important step across all the clinical areas since it can be one of the reasons of spreading infection.31

These are key phrases which provide the adequate time for the systems to gather resources and capacity to help in breaking the chain of transmission. The virus infects exponentially which is very clear and many will contract it very soon. State should provide premises to serve as isolation ward and quarantine spaces. All hospitals should use their full area to create control committees to monitor activities to ensure protocols are implemented for effective control. The loop has to be complete, involving community systems, governments and primary health-care workers are key, since not everyone will report to hospitals, if community transmission will be rampant.

The comfort and willingness in working for a health system which has an effective plan, magnifies many times in a pandemic. Protocols in local languages for better understanding and awareness material based on science research have been useful. Offering free transport service between work and home, childcare support and meal vouchers can reduce domestic stress and allow single-minded effort towards the health service.83

Apart from the various negative effect imposed by the pandemic, positive vibes of it cannot be neglected. The pandemic situation significantly improves air quality in different cities across the country, reduces GHGs emission, lessens water pollution and noise, and reduces the pressure on the tourist destinations, which may assist with the restoration of the ecological systems.84 These changes may be short term but are important for maintenance of environmental balance. Apart from this, various successful models like that of Dharavi and Kerala model were implemented which restricted the cases to a minimum through observing the spread in the localities, studying the prototype of spread, and strict use of methods to control the disease in Kerala. Dharavi restricted the coronavirus cases with a strategy of attack not defence and elucidated triumphant results in 2 months.85

There are more than 56 COVID-19 candidate vaccines in clinical evaluation of which 13 are in phase III trials and another 166 candidate vaccines are in preclinical evaluation (Table 1). All top candidate vaccines will be delivered through intra-muscular injection and are designed for a two-dose schedule.86 More recently our group has suggested the combinatorial use of childhood vaccines (BCG, MMR and OPV) along with the COVID-19 dedicated vaccines could be a potential strategy to control the COVID-19 pandemic worldwide.87

Table 1 Prospective Therapeutic Representative Against COVID-19 Disease

Strain B.1.1.7 was first detected in the United States in December 2020 followed by B.1.351, in South Africa P.1, in Brazil and Japan, B.1.427 and B.1.429. These two variants were first identified in California in February 2021. COVID-19 variant from India is B.1.617; one of the lineages is B.1.617.2, which has been detected most frequently in the US and the U.K.88 Recently the black fungus is now maiming COVID-19 patients in India. Mucormycosis is an invasive infection caused by a class of molds called mucormycetes. It has an overall mortality rate of 50%, and may be being triggered by the use of unhygienic oxygen cylinders and steroids, a life-saving treatment for severe and critically ill COVID-19 patients.89

In this review, we have been discussed the stories related to prevention strategies, chemotherapeutics and vaccines strategies to manage COVID-19. Apart from that we have discussed the challenges faced by HCWs and their prevention. Combating COVID-19 is still a challenge also due to the poorly-based counsel for using an experimental amalgamation of antimalarials and antimicrobials as treatment; the use of steroids; and antihypertensive drugs during the course of the disease. Interruption of the transmission of SARS-CoV-2 through engineered vaccines is top in the priority followed by the intense research to find out the potential treatment to control this viral infection.

All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

There is no funding to report.

Divakar Sharma and Dileep Tiwari were associated with Hericure Healthcare Pvt Ltd. Currently, Divakar Sharma is working in Maulana Azad Medical College at the time of this review. The authors reported no other potential conflicts of interest for this work.

1. Hoffmann M, Kleine-Weber H, Krger N, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271280. doi:10.1016/j.cell.2020.02.052

2. Fischer F, Raiber L, Boscher C, et al. COVID-19 and the elderly: who cares? Front Public Health. 2020;8:151. doi:10.3389/fpubh.2020.00151

3. Vahia IV, Blazer DG, Smith GS, et al. COVID-19, mental health and aging: a need for new knowledge to bridge science and service. Am J Geriatr Psychiatry. 2020;28(7):695. doi:10.1016/j.jagp.2020.03.007

4. COVID-19. Tracker India; 2020. Available from: https://www.COVID19india.org/. Accessed April 15, 2020.

5. Census-India. 2011. Available from: https://censusindia.gov.in/2011-Common/CensusData2011.html. Accessed April 15, 2020.

6. Mishra VK. Indias projected aged population (65?), projected life expectancy at birth and insecurities faced by aged population. Ageing International. 2020;45:7284.

7. De Witt Huberts J, Greenland K, Schmidt W-P, et al. Exploring the potential of antimicrobial hand hygiene products in reducing the infectious burden in low-income countries: an integrative review. Am J Infect Control. 2016;44(7):764771. doi:10.1016/j.ajic.2016.01.045

8. U.S. Food and Drug Administration. Temporary policy for preparation of certain alcoholbased hand sanitizer products during the public health emergency (COVID-19). Guidance for Industry; March, 2020. Available from: https://www.fda.gov/media/136289/download. Accessed July 21, 2021.

9. Edwards J, Patel G, Wareham DW. Low concentrations of commercial alcohol hand rubs facilitate growth of and secretion of extracellular proteins by multidrug-resistant strains of Acinetobacter baumannii. J Med Microbiol. 2007;56(12):15951599. doi:10.1099/jmm.0.47442-0

10. healthcare-in-europe.com [Internet]. Will resistant bacteria be the end of alcohol hand sanitizers? 2018. Available from: https://healthcare-in-europe.com/en/news/will-resistant-bacteria-be-the-end-of-alcohol-hand-sanitizers.html#. Accessed July 21, 2021.

11. Lan J, Song Z, Miao X, et al. Skin damage among health care workers managing coronavirus disease-2019. J Am Acad Dermatol. 2020;82(5):12151216. doi:10.1016/j.jaad.2020.03.014

12. The Government of India issues simple guidelines, for controlling spread of COVID-19 in densely populated areas. Available from: https://pib.gov.in/PressReleseDetailm.aspx?PRID=1614064. Accessed July 21, 2021.

13. TIFAC explores best methods to revive Indian economy post COVID-19.Available from: https://dst.gov.in/tifac-explores-best-methods-revive-indian-economy-post-COVID-19. Accessed July 21, 2021.

14. TDB approves support for indigenous company for ramping up production of COVID-19 diagnostic kits.Available from: https://dst.gov.in/tdb-approves-support-indigenous-company-ramping-production-COVID-19-diagnostic-kits. Accessed July 21, 2021.

15. NBRI scientists develop herbal hand-sanitiser.Available from: https://vigyanprasar.gov.in/isw/NBRI-scientists-develop-herbal-hand-sanitiser.html. Accessed July 21, 2021.

16. Indian researchers to go for clinical trial of sepsis drug against novel coronavirus.Available from: https://vigyanprasar.gov.in/wp-content/uploads/Indian-researchers-to-go-for-clinical-trial-of-sepsis-drug-against-novel-coronavirus-21apr20.pdf. Accessed July 21, 2021.

17. Advisory_on_Cepheid_Xpert_Xpress_SARS_CoV2_testing.Available from: https://icmr.nic.in/sites/default/files/upload_documents/Advisory_on_Cepheid_Xpert_Xpress_SARS_CoV2_testing.pdf. Accessed July 21, 2021.

18. AMU alumnus develops COVID-19 testing kit, approved by ICMR. Available from: https://www.amu.ac.in/about3.jsp?did=2495. Accessed July 21, 2021.

19. Bione launches rapid COVID-19 at-home screening test kit after ICMR approval.Available from: https://zeenews.india.com/india/bione-launches-rapid-COVID-19-at-home-screening-test-kit-after-icmr-approval-2273752.html. Accessed July 21, 2021.

20. Wu F, Zhao S, Yu B, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv. 2020;2020:919183. doi:10.1101/2020.01.24.919183

Excerpt from:
Challenges and Successes of Dealing with COVID-19 in India | RRTM - Dove Medical Press

Recent Advances in the Use of Mesoporous Silica Nanoparticles for the Diagnosis of Bacterial Infections – DocWire News

This article was originally published here

Int J Nanomedicine. 2021 Sep 24;16:6575-6591. doi: 10.2147/IJN.S273062. eCollection 2021.

ABSTRACT

Public awareness of infectious diseases has increased in recent months, not only due to the current COVID-19 outbreak but also because of antimicrobial resistance (AMR) being declared a top-10 global health threat by the World Health Organization (WHO) in 2019. These global issues have spiked the realization that new and more efficient methods and approaches are urgently required to efficiently combat and overcome the failures in the diagnosis and therapy of infectious disease. This holds true not only for current diseases, but we should also have enough readiness to fight the unforeseen diseases so as to avoid future pandemics. A paradigm shift is needed, not only in infection treatment, but also diagnostic practices, to overcome the potential failures associated with early diagnosis stages, leading to unnecessary and inefficient treatments, while simultaneously promoting AMR. With the development of nanotechnology, nanomaterials fabricated as multifunctional nano-platforms for antibacterial therapeutics, diagnostics, or both (known as theranostics) have attracted increasing attention. In the research field of nanomedicine, mesoporous silica nanoparticles (MSN) with a tailored structure, large surface area, high loading capacity, abundant chemical versatility, and acceptable biocompatibility, have shown great potential to integrate the desired functions for diagnosis of bacterial infections. The focus of this review is to present the advances in mesoporous materials in the form of nanoparticles (NPs) or composites that can easily and flexibly accommodate dual or multifunctional capabilities of separation, identification and tracking performed during the diagnosis of infectious diseases together with the inspiring NP designs in diagnosis of bacterial infections.

PMID:34602819 | PMC:PMC8478671 | DOI:10.2147/IJN.S273062

Read the rest here:
Recent Advances in the Use of Mesoporous Silica Nanoparticles for the Diagnosis of Bacterial Infections - DocWire News

NanoView Biosciences Announces the Release of the ExoView R200 Platform – WWNY

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 10 hours ago

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NanoView Biosciences today announced the release of the ExoView R200, its next-generation platform for the sensitive detection and characterization of extracellular vesicles (EVs), including exosomes and viruses.

Launched in 2019, ExoView provides high-resolution sizing, counting and phenotyping of exosomes and viral vectors at the individual extracellular vesicle level. Understanding the biomarkers carried by extracellular vesicles has potential for diagnostic, prognostic, and therapeutic use for a broad range of diseases.

The original ExoView R100platform revolutionized EV detection, delivering EV sizing down to 50 nm, with high sensitivity and specificity that cannot be matched by existing EV characterization. The ExoView platform also requires low sample input, no extensive sample preparation or purification, and minimal hands-on time.

NanoView Biosciences is now taking the ExoView platform one step further with the release of the ExoView R200. In addition to the capabilities of the ExoView R100, the R200 new features include:

"We are very excited about the release of the R200 and the benefits it will provide to researchers in the EV field", said Jerry Williamson, CEO of NanoView Biosciences, "Based on the tremendous success of the ExoView platform, we have been working closely with our customers and scientific advisory boardto see what more is needed to address critical questions about EVs. We believe that the additional capability of the R200 will advance our goal to better understand the biological role of extracellular vesicles and their potential use as biomarkers for personalized medicine."

The ExoView R200 is available now, including upgrade paths for existing R100 users. For more information visit http://www.nanoviewbio.com.

About NanoView BiosciencesNanoView Biosciences, a Boston-based, privately-held company, is focused on enabling worldwide life science researchers to better understand the biological role of extracellular vesicles, including exosomes and viral vectors, and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The Company's proprietary products, including the ExoView R100 and R200 platforms, have been designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision nanomedicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.

View original content:

SOURCE NanoView Biosciences

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Read more:
NanoView Biosciences Announces the Release of the ExoView R200 Platform - WWNY

Corrigendum for the article Anti-Cancer Activity Based on the High Doc | IJN – Dove Medical Press

Xu M, Yao C, Zhang W, Gao S, Zou H, Gao J. Int J Nanomedicine. 2021;16:27352749.

The authors have advised the Acknowledgment statement on page 2748 is incorrect. The acknowledgment section should read as follows:

The authors acknowledge the formulation for the docetaxel in Poly(2-oxazoline) micelles previously developed and published by the Kabanov lab with reference to Seo Y, Schulz A, Han Y, et al. Poly (2-oxazoline) block copolymer based formulations of taxanes: effect of copolymer and drug structure, concentration, and environmental factors. Polym Adv Technol. 2015;26(7):837850 (https://doi.org/10.1002/pat.3556).24 The current article reports the authors original research evaluating this polymeric micelle formulation of docetaxel in their own animal models. Dr Jing Gao wishes to acknowledge her time spent as a visiting scholar to the Kabanov lab at UNC-Chapel Hill from 2013-2014. This study was supported by Military Medical Innovation Project (16CXZ032), National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09J18107-003, 2018ZX0 9721003-005-009) and NSFC projects (No. 81773278, 81702491).

Read the original article

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more:
Corrigendum for the article Anti-Cancer Activity Based on the High Doc | IJN - Dove Medical Press

‘Soft’ Graphene-Containing Electrodes That Adapt to Living Tissue – Printed Electronics World

Researchers from The University of Manchester and Harvard University have collaborated on a pioneering project in bioengineering, producing metal-free, hydrogel electrodes that flex to fit the complex shapes inside the human body.

Replacing rigid metals

Tringides and Mooney, in collaboration with the Nanomedicine Lab in Manchester, identified a mixture of graphene flakes and carbon nanotubes as the best conductive filler, replacing the use of traditional rigid metals.

Cinzia Casiraghi, Professor of Nanoscience from the NGI and Department of Chemistry at Manchester, said: "This work demonstrates that high-quality graphene dispersions - made in water by a simple process based on a molecule that one can buy from any chemical supply - have strong potential in bioelectronics. We are very interested in exploiting our graphene (and other 2D materials) inks in this field."

Collaborative effort

Kostas Kostarelos, Professor of Nanomedicine and leader of the Nanomedicine Lab, added: "This truly collaborative effort between three institutions is a step forward in the development of softer, more adaptable and electroactive devices, where traditional technologies based on bulk and rigid materials cannot be applied to soft tissues such as the brain."

Source: University of Manchester

Top image source: Wyss Institute at Harvard University

More:
'Soft' Graphene-Containing Electrodes That Adapt to Living Tissue - Printed Electronics World

Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 – The Market Writeuo – The…

The Latest research study released by DBMR Global Nanotechnology Market with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. The report shows market share, size, trends, growth, trends, applications, competition analysis, development patterns, and the correlations between the market dynamics and forecasts for 2020 to 2027 time-frames. The report aims to provide an overview of global Nanotechnology Market with detailed market segmentation by product/application and geography. The report provides key statistics on the Market status of the players and offers key trends and opportunities in the market. Research report has been compiled by studying the market in-depth along with drivers, opportunities, restraints & other strategies as well as new-developments that can help a reader to understand the exact situation of the market along with the factors that can limit or hamper the market growth and the report also has been updated with Impacts & effects of Coronavirus pandemic and how it has influenced consumer behavior& the growth of the market as well as industries.

The Global Nanotechnology Market is expected to reach USD 24.56 billion by 2025, from USD 7.24 billion in 2017 growing at a CAGR of 16.5% during the forecast period of 2020 to 2025

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanotechnology-market&ab

Nanoscience is the study of extremely small things. The development of nanotechnology is being growing in many fields, as it has various applications, such as in chemistry, biology, physics, materials science and engineering. Nanotechnology deals with the use of nanoparticle of size of 1 to 100 nm to be used in all major field of medical. Materials designed from nanotechnology are lighter, stronger and more durable. In oncology research, nanotechnology assists in cancer eradication. Nanotechnology based device are also used in fitness monitoring. Smartphone apps and bracelets are developed based on nanotechnology concept. A nano based device is used to sense the body temperature, heartbeat and others which are sent back to the reader. After analysing the temperature and heartbeat, medical staff monitors the condition. All these nano based devices helps to drive the market. For elder people, battery-free printed graphene sensors are also developed which helps in gathering the health condition of the elder population, enables remote healthcare and improves the quality of life. In diagnostic and prevention, nanotechnology plays a vital role in cancer diagnostics. Nanotechnology based devices can detects the biomarker produced by the circulating tumor cells (CTCs) on the onset of cancer. Based on nanotechnology, two main methods of circulating tumor cells (CTC) isolations are magnetic and microfluidic methods. In clinical development fluorescent nano sensors are used for in-vivo monitoring of biomarkers. Another application of nanotechnology is nanomedicine which has potential application in diagnosis and therapy medicine for regeneration of tissues and organs.

This Nanotechnology Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Nanotechnology Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this reportGlobal Nanotechnology Marketwill rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Nanotechnology Market includes comprehensive information derived from depth study on Nanotechnology Industry historical and forecast market data. Global Nanotechnology Market Size To Expand moderately as the new developments in Nanotechnology and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-nanotechnology-market?ab

Nanotechnology Market report provides depth analysis of the market impact and new opportunities created by theCOVID19/CORONAVirus pandemic. Report covers Nanotechnology Market report is helpful for strategists, marketers and senior management, And Key Players in Nanotechnology Industry.

List of Companies Profiled in the Nanotechnology Market Report are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanotechnology-market&Ab

Nanotechnology Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Nanotechnology market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Nanotechnology report comes into play.

The Segments and Sub-Section of Nanotechnology Market are shown below:

By Type (Nano composites, Nano materials, Nano tools, Nano devices, Others)

By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others)

By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others

Market Size Segmentation by Region & Countries (Customizable):

Key questions answered

What impact does COVID-19 have made on Global Nanotechnology Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Nanotechnology market?

What are the key concerns of the five forces analysis of the Global Nanotechnology market?

What are different prospects and threats faced by the dealers in the Global Nanotechnology market?

What are the strengths and weaknesses of the key vendors?

Market Segmentation: Global Nanotechnology Market

The global nanotechnology market is segmented based on product type, application, industry and geographical segments.

By Product Type (Nano Composites, Nano Materials, Nano Tools, Nano Devices, Others), By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others), By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Based on product type , the market is segmented into nano-composites and nano materials, nano tools, nano devices, and others. Nano-composites are further sub segmented into nanoparticles, nanotubes and nano clays. Nano materials are further sub-segmented into nano fibers, nano ceramic products and nano magnetics. Nano tools are further sub-segmented into nanolithography tools and scanning probe microscopes. Nanodevices are further sub-segmented into nanosensors and nanoelectronics.

On the basis of application, the market is further segmented into healthcare, environment, energy, food & agriculture, information & technology and others.

Based on industries, the market is segmented into electronics, cosmetics, pharmaceutical, biotechnology and others.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Strategic Points Covered in Table of Content of Global Nanotechnology Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Nanotechnology market

Chapter 2: Exclusive Summary the basic information of the Nanotechnology Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Nanotechnology

Chapter 4: Presenting the Nanotechnology Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Nanotechnology market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Nanotechnology Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

See original here:
Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 - The Market Writeuo - The...

Faculty Positions of Biomedical Sciences and Engineering and Molecular Science and Engineering job with South China University of Technology (SCUT) |…

About SCUT

South China University of Technology (SCUT) is a leading public research-intensive educational institution in China. Located in Guangzhou, a thriving metropolis in the Pan Pearl River Delta Economic Area and the Guangdong-Hong Kong-Macao Greater Bay Area in South China, it is now one of the 36 Class-A universities under the Chinese Ministry of Education (MoE)s national Double First Class University Plan.

SCUT is a comprehensive research university with particular strengths in engineering, sciences, medicine, business, economics, humanities, law and other disciplines. According to Clarivate Analytics, its number of disciplines listed in the ESI global top 1 is tied for 8th place nationwide.

About GZIC

On March 15, 2017, the agreement of constructing the Guangzhou International Campus(GZIC) of SCUT was signed by four parties: the Ministry of Education (MoE) of the Peoples Republic of China, Guangdong provincial government, Guangzhou municipal government and SCUT.

It is the first and only campus that MoE cooperates with the university and the local governments to build a world-class university in cooperation with top overseas universities. The campus aims to drive innovation and serve the country through education and research activities, as well as contribute to the development of the Guangdong-Hong Kong-Macao Greater Bay Area.

Located on the south bank of Guangzhou International Innovation City, GZIC covers an area of 110 hectares. The first-phase campus has already opened since September 2019, and the remainder is marked for completion by the end of 2021. The total investment of the campus is estimated to exceed 20 billion RMB. Upon completion, the campus will enroll about 12,000 students and employ 1,600 staff.

In line with SCUTs strength in engineering, the Guangzhou International Campus will focus on disciplines such as intelligent manufacturing, biological medicine, advanced materials, ecological environment, AI and other emerging engineering and interdisciplinary fields.

Ten new engineering schools and a host of cross disciplinary research institutes will be setup on the campus. So far, four schools have been established, namely, the School of Biomedical Sciences and Engineering, the Shien-Ming Wu School of Intelligent Engineering, the School of Molecular Science and Engineering, and the School of Microelectronics.

The schools offer undergraduate, master, and doctoral programs. Enrollment for graduate students has started since September 2018, while undergraduate enrollment began in September 2019 in the fields of biomedical engineering, robotics engineering, intelligent manufacturing engineering, molecular science and engineering, and microelectronics science and engineering.

Schools and Disciplines for Recruitment

School of Biomedical Sciences and Engineering

Disciplines for Recruitment:

Tumor Biology, Systems Biology, Single-cell Biology, Computational and Genomic Medicine, Immunology and Immune Engineering, Biomedical Big Data and Precision Medicine, Stem Cell and Tissue Engineering, Biomaterials, Nanomedicine and Drug Delivery, Biomedical Imaging and Molecular Imaging, Regulatory Science for Medical Devices, etc.

Outstanding scholars in these fields are cordially invited to apply.

Contact: Ms.Tu

Tel: +86 20 39380916

Email: tuzl@scut.edu.cn

Website: https://www2.scut.edu.cn/bmse/

School of Molecular Science and Engineering

Disciplines for Recruitment:

Outstanding scholars in Physics, Chemistry, Materials, Biomedical Science and other related areas are cordially invited to apply, including but not limited to the fields of Soft Matter Functional and Intelligent Advanced Materials, Green Chemistry and Environmental Science, Special Materials under Extreme Conditions, Advanced Information and Energy Materials, Advanced Health and Medical Materials Basic Research and Applied Engineering, etc.

Contact: Ms. Dai

Tel: +86 20 22237323

Email: daian@scut.edu.cn

Website: https://www2.scut.edu.cn/MoSE/

Apart from the areas listed above, qualified scholars working in related interdisciplinary frontiers are also welcome to apply for faculty positions.

Faculty Positions

Assistant Professor or Associate Professor (Tenure-Track)

Associate Professor or Full Professor (Tenured)

Working Conditions

Living Benefits

Salary: a competitive salary corresponding to the position will be provided comparable to that of top international universities. For applicants who have obtained faculty positions in world-class universities, the salary can be negotiated with reference to the applicant's current salary and benefits.

Housing benefits: on-campus rental apartment (subject to application and approval) and a housing subsidy ranging from RMB 1 million to 10 million may be provided according to relevant policies of Guangdong province and Guangzhou municipality.

Other benefits: according to relevant Chinese policies for non-Chinese citizens, the university will pay the employee component of Chinese social insurance, and help with childrens enrollment in the universitys kindergarten, primary, and secondary schools.

Contact Information

Please send the application materials to the email address of the contact person for the respective school or the academic recruitment email address of the campus. Your application materials should include your curriculum vitae, a research plan, and a teaching plan (all in PDF format). In addition, your three referees should send their recommendation letters to the academic recruitment email address of the campus, indicating the name of the applicant/s as the subject of the email.

The academic recruitment email address of the campus: academic@scut.edu.cn

If you need further information about us, please visit the official websites Wechat Platform of South China University of Technology and Guangzhou International Campus. We will also provide timely answers to application questions and policy inquiries through schools contact information and academic recruitment mailbox.

Office of Human Resources and Academic Planning

-Contact: Mr. Pei, Ms. Wang

-Tel: +86 20 81181618 +86 20 81181613

-SCUT Website: https://www.scut.edu.cn/

-GZIC Website: http://www2.scut.edu.cn/gzic/

This advertisement of faculty recruitment is effectively all year round. Warmly welcome to join us!

The rest is here:
Faculty Positions of Biomedical Sciences and Engineering and Molecular Science and Engineering job with South China University of Technology (SCUT) |...

Multi-Walled Carbon Nanotubes Market Report 2021 – Global Production Capacities for MWCNTS Historical and Forecast to 2031 – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "The Global Market for Multi-Walled Carbon Nanotubes 2021-2031" report has been added to ResearchAndMarkets.com's offering.

There has been a resurgence of industrial interest in multi-walled carbon nanotubes (MWCNT) over the last two years, after producers had previously reduced or abandoned production. LG Chem has recently launched the world's largest MWCNT manufacturing plant in Korea (1,700 tons total).

At the end of 2020, Carbice Corporation raised $15 million to develop CNTs for thermal management in electronics. Cabot Corporation acquired Shenzhen Sanshun Nano New Materials Co., Ltd (SUSN) for approximately $115 million.

MWCNTs are mainly used as substitute additives of carbon black in conductive plastics and composites applications and as additives in lithium-ion battery electrodes. MWCNT powders, arrays, sheets, flakes, films and yarns have found applications in semoconductors, power cables, automotive coatings, polymer composites, coatings, aerospace, sensors, heaters, filters and biomedicine.

Report contents include:

Key Topics Covered:

1 Executive Summary

1.1 The global market for carbon nanotubes in 2021

1.1.1 Demand for Multi-walled carbon nanotubes (MWCNTs) increasing

1.1.2 Industry developments 2020-2021

1.2 Exceptional properties

1.3 Commercial products

1.3.1 Applications

1.3.2 Key players

1.3.3 Production capacities in 2021

1.3.4 Market demand, metric tons (MT)

1.4 Carbon nanotubes market challenges

2 Ovewview of Carbon Nanotubes

2.1 Properties

2.2 Comparative properties of CNTs

3 Carbon Nanotube Synthesis And Production

4 Carbon Nanotubes Patents

5 Carbon Nanotubes Pricing And Price Drivers

6 3D Printing

7 Adhesives

8 Aerospace

9 Automotive

10 Batteries

10.2.1 Cnts In Electric Vehicle Batteries

10.2.2 Nanomaterials In Lithium-Sulfur (Li-S) Batteries

10.2.3 Nanomaterials In Sodium-Ion Batteries

10.2.4 Nanomaterials In Lithium-Air Batteries

10.2.5 Flexible And Stretchable Batteries In Electronics

10.2.6 Flexible And Stretchable Libs

10.2.6.1 Fiber-Shaped Lithium-Ion Batteries

10.2.6.2 Stretchable Lithium-Ion Batteries

10.2.6.3 Origami And Kirigami Lithium-Ion Batteries

10.2.6.4 Fiber-Shaped Lithium-Ion Batteries

10.3.1 Materials

11 Composites

12 Conductive Inks

13 Construction

13.3.1 Cement

13.3.2 Asphalt Bitumen

14 Filtration

15 Fuel Cells

16 Life Sciences And Medicine

16.3.1 Drug Delivery

16.3.2 Imaging And Diagnostics

16.3.3 Implants

16.3.4 Medical Biosensors

16.3.5 Woundcare

17 Lubricants

18 Oil And Gas

19 Paints And Coatings

20 Photovoltaics

21 Rubber And Tires

22 Sensors

23 Smart Textiles And Apparel

24 Supercapacitors

25 Other Markets

26 Collaborations

27 Company Profiles

28 Research Methodology

29 References

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/2z3fem

Continue reading here:
Multi-Walled Carbon Nanotubes Market Report 2021 - Global Production Capacities for MWCNTS Historical and Forecast to 2031 - ResearchAndMarkets.com -...

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – LionLowdown

Nanomedicine Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

Nanomedicine Market Drivers and Restrains:Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/39223

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/39223

Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

MAJOR TOC OF THE REPORT

Chapter One: Nanomedicine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Nanomedicine Market Competition, by Players

Chapter Four: Global Nanomedicine Market Size by Regions

Chapter Five: North America Nanomedicine Revenue by Countries

Chapter Six: Europe Nanomedicine Revenue by Countries

Chapter Seven: Asia-Pacific Nanomedicine Revenue by Countries

Chapter Eight: South America Nanomedicine Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Nanomedicine by Countries

Chapter Ten: Global Nanomedicine Market Segment by Type

Chapter Eleven: Global Nanomedicine Market Segment by Application

Chapter Twelve: Global Nanomedicine Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Nanomedicine Market Report at: https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

https://lionlowdown.com/

Go here to see the original:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - LionLowdown

Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution – The Hub at Johns Hopkins

ByHub staff report

Philanthropist and Johns Hopkins Medicine trustee David M. Rubenstein has made a $15 million commitment to the Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins to support the department's research.

Image caption: David M. Rubenstein

The gift, his second pledge of that size to the department, will establish the David M. Rubenstein Precision Medicine Center of Excellence and will deepen his support for basic science researchers focused on the development of therapeutic approaches to preserve and restore hearing. Three strategic project teams, working in collaboration with researchers across Johns Hopkins University, will explore inner ear hair cell repair, sensory neuron repair, and nanomedicine drugs and drug delivery.

Rubenstein's gift will also support core facilities for these teams, consisting of:

Additionally, funds from this gift will support an annual conference and a speaker series.

"David's initial gift has helped Johns Hopkins researchers make important discoveries in several crucial areas related to hearing and hearing loss," said Paul B. Rothman, dean of the School of Medicine and CEO of Johns Hopkins Medicine. "But there is so much more to be done in this area, and once again, David has stepped forward. We are grateful for all that his generosity has made possible so far, and we are even more excited about what this new commitment will allow us to accomplish going forward. In the end, this work will help the millions of people who struggle every day with hearing problems."

Rubenstein's earlier gift to the department, made in 2015, funded the creation of an endowment to support cross-institutional accelerator grants. Any researcher at Johns Hopkins may apply for a grant for new or existing research to further the understanding of hearing. Grant amounts vary. In FY19, a total of $800,000 was awarded to seven different research projects, plus research core support. The earlier gift also established an endowed professorship, providing critical funds in perpetuity to support a leading faculty member in research and teaching.

"David's support has enabled innovative research projects that leverage the expertise and imagination of scientists, engineers, and clinicians from across Johns Hopkins," said Paul Fuchs, the inaugural David M. Rubenstein Research Professor of OtolaryngologyHead and Neck Surgery. "This is particularly important as we move from basic discovery of molecular and cellular mechanisms, to targeting these for therapeutic benefit. Current efforts employ gene therapy to correct inherited deafness, to regenerate cochlear hair cells, or to enhance protection from acoustic trauma. Other strategies aim to re-establish lost connections from inner ear to brain, a significant contributor to noise-induced and age-related hearing loss."

To learn more about some of the advances made possible through Rubenstein's generosity and hear from the researchers, visit the Otolaryngology-Head and Neck Surgery YouTube playlist.

Rubenstein is a founder and co-executive chairman of The Carlyle Group, a global investment firm. Rubenstein is a noted philanthropist and a long-time member of the Johns Hopkins Medicine board of trustees.

"It is a privilege to support the talented and committed researchers and doctors of Johns Hopkins who are helping people suffering from hearing loss," Rubenstein said. "I am impressed with the progress made in recent years and hope this new gift will accelerate and deepen those efforts."

Read more:
Johns Hopkins Department of Otolaryngology-Head and Neck Surgery receives $15M contribution - The Hub at Johns Hopkins

NanoView Biosciences Strengthens Executive Team – BioSpace

BOSTON, Jan. 13, 2021 /PRNewswire/ -- NanoView Biosciences, Inc., the leader in single exosome characterization, today announced the expansion of its management team with the appointment of David Hanlon, Ph.D. to the position of Vice President, Strategic Collaborations. The addition is a key part of the company's strategy to create and expand strategic partnerships within the life sciences, pharmaceutical and diagnostics markets.

Dr. Hanlon brings over 20 years of product development and commercialization experience to NanoView, most recently serving as Vice President of Strategic Collaborations at Quanterix. Over the last 12 years he has led the strategic marketing efforts and established an assay service laboratory to support new applications and drive commercial interest. He has held leadership roles in several life sciences and diagnostics companies, including Hologic (formerly Cytyc), where he directed multiple biomarker programs to develop diagnostic tests for cervical cancer. Dr. Hanlon received his Ph.D. in Biochemistry from the University of Illinois, Urbana-Champaign and B.S. from Worcester Polytechnic Institute.

"We are very excited to welcome David Hanlon to NanoView as we enter a significant growth phase for the Company," said Jerry Williamson, CEO of NanoView Biosciences. "His expertise in establishing and expanding strategic relationships for life science technology providers will accelerate the success of NanoView and we look forward to his contribution on our executive team."

Commenting on his new role, Dr. Hanlon added, "I am very excited to be joining NanoView, a ground-breaking organization that has developed a novel platform solution to characterize extracellular vesicles in human disease. I look forward to working with the leadership team as the organization continues to expand its product and service offerings to help researchers and clinicians leverage the potential of exosomes in this era of personalized medicine."

NanoView has created ExoView, a unique and proprietaryplatform which provides high-resolution sizing, counting and phenotyping of exosomes and viral vectors at the single vesicle level. Understanding the molecules carried by extracellular vesicles has potential for diagnostic, prognostic, and therapeutic use for a broad range of diseases. ExoView requires low sample input, no extensive sample preparation or purification, and minimal hands-on time. It can be used directly with complex biological samples.

The ExoView platform is designed For Research Use Only. It is not for use in diagnostic procedures.

About NanoView Biosciences

NanoView Biosciences, a Boston-based, privately-held company, is focused on enabling worldwide life science researchers to better understand the biological role of extracellular vesicles, including exosomes and viral vectors, and their potential use as biomarkers for improving the diagnosis, prognosis, treatment, and monitoring of disease. The Company's proprietary product, the ExoView platform, was designed to fully characterize exosomes and other extracellular vesicles for use in research and in the implementation of precision nanomedicine. ExoView is a high-throughput, cost-effective analysis platform that is easy to use and does not require purification or large sample volumes to accurately analyze exosomes.

http://www.nanoviewbio.com

View original content:http://www.prnewswire.com/news-releases/nanoview-biosciences-strengthens-executive-team-301207135.html

SOURCE NanoView Biosciences

See the rest here:
NanoView Biosciences Strengthens Executive Team - BioSpace

"Greening Biomaterials and Scaffolds Used in Regenerative Medicine – Newswise

Newswise Green manufacturing is becoming an increasingly critical process across industries, propelled by a growing awareness of the negative environmental and health impacts associated with traditional practices. In the biomaterials industry, electrospinning is a universal fabrication method used around the world to produce nano- to microscale fibrous meshes that closely resemble native tissue architecture. The process, however, has traditionally used solvents that not only are environmentally hazardous but also pose a significant barrier to industrial scale-up, clinical translation, and, ultimately, widespread use.

Researchers atColumbia Engineeringreport that they have developed a "green electrospinning" process that addresses many of the challenges to scaling up this fabrication method, from managing the environmental risks of volatile solvent storage and disposal at large volumes to meeting health and safety standards during both fabrication and implementation. The teams newstudy, published June 28, 2021, by Biofabrication, details how they have modernized the nanofiber fabrication of widely utilized biological and synthetic polymers (e.g. poly--hydroxyesters, collagen), polymer blends, and polymer-ceramic composites.

The study also underscores the superiority of green manufacturing. The groups green fibers exhibited exceptional mechanical properties and preserved growth factor bioactivity relative to traditional fiber counterparts, which is essential for drug delivery and tissue engineering applications.

Regenerative medicine is a $156 billion global industry, one that is growing exponentially. The team of researchers, led byHelen H. Lu, Percy K. and Vida L.W. Hudson Professor ofBiomedical Engineering, wanted to address the challenge of establishing scalable green manufacturing practices for biomimetic biomaterials and scaffolds used in regenerative medicine.

We think this is a paradigm shift in biofabrication, and will accelerate the translation of scalable biomaterials and biomimetic scaffolds for tissue engineering and regenerative medicine, said Lu, a leader in research on tissue interfaces, particularly the design of biomaterials and therapeutic strategies for recreating the bodys natural synchrony between tissues. Green electrospinning not only preserves the composition, chemistry, architecture, and biocompatibility of traditionally electrospun fibers, but it also improves their mechanical properties by doubling the ductility of traditional fibers without compromising yield or ultimate tensile strength. Our work provides both a more biocompatible and sustainable solution for scalable nanomaterial fabrication.

The team, which included several BME doctoral students from Lus group, Christopher Mosher PhD20 and Philip Brudnicki, as well as Theanne Schiros, an expert in eco-conscious textile synthesis who is also a research scientist at Columbia MRSEC and assistant professor at FIT, applied sustainability principles to biomaterial production, and developed a green electrospinning process by systematically testing what the FDA considers as biologically benign solvents (Q3C Class 3).

They identified acetic acid as a green solvent that exhibits low ecological impact (Sustainable Minds Life Cycle Assessment) and supports a stable electrospinning jet under routine fabrication conditions. By tuning electrospinning parameters, such as needle-plate distance and flow rate, the researchers were able to ameliorate the fabrication of research and industry-standard biomedical polymers, cutting the detrimental manufacturing impacts of the electrospinning process by three to six times.

Green electrospun materials can be used in a broad range of applications. Lus team is currently working on further innovating these materials for orthopaedic and dental applications, and expanding this eco-conscious fabrication process for scalable production of regenerative materials.

"Biofabrication has been referred to as the fourth industrial revolution' following steam engines, electrical power, and the digital age for automating mass production, noted Mosher, the studys first author. This work is an important step towards developing sustainable practices in the next generation of biomaterials manufacturing, which has become paramount amidst the global climate crisis."

###

The study is titled Green electrospinning for biomaterials and biofabrication.

Authors are: Christopher Z. Mosher (A), Philip A.P. Brudnickia (A), Zhengxiang Gonga (A), Hannah R. Childs (A), Sang Won Lee (A),Romare M. Antrobus (A)Elisa C. Fang (A), Theanne N. Schiros (B,C)and Helen H. Lu (A,B)

A. Biomaterials and Interface Tissue Engineering Laboratory, Department of Biomedical Engineering, Columbia University

B. Materials Research Science and Engineering Center, Columbia University

C. Science and Mathematics Department, Fashion Institute of Technology

This work was supported by the National Institutes of Health (NIH-NIAMS 1R01-AR07352901A), the New York State Stem Cell ESSC Board (NYSTEM C029551), the DoD CDMRP award (W81XWH-15- 1-0685), and the National Science Foundation Graduate Research Fellowship (DGE-1644869, CZM). The CD analysis system was supported by NIH grant 1S10OD025102-01, and TNS was supported as part of the NSF MRSEC program through Columbia in the Center for Precision Assembly of Superstratic and Superatomic Solids (DMR-1420634).

The authors declare no competing interest.

Columbia Engineering

Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 220 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The Schools faculty are at the center of the Universitys cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, Columbia Engineering for Humanity, the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity.

Link:
"Greening Biomaterials and Scaffolds Used in Regenerative Medicine - Newswise

McMaster University researchers awarded more than $3M in Federal funds for projects – insauga.com

Eleven researchers working out of Hamilton's McMaster University have been awarded almost $3.3 million from the Federal Government for projects deemed to be "on the cutting edge of science andinnovation."

On Wednesday (Aug. 11), Francois-Philippe Champagne, Minister of Innovation, Science and Industry, announced that more than $77 million had been earmarked to support 332 research infrastructure projects at 50 universities acrossCanada.

The funding, made possible through the Canada Foundation for Innovation's (CFI) John R. Evans Leaders Fund (JELF), is expected to help universities attract and retain topresearchers.

"From developing sustainable building materials to creating new laboratories based on Indigenous principles and community engagement, these awards support essential and urgent research," said CFI president and CEO Roseann O'Reilly Runte, in a pressrelease.

"With the necessary spaces and tools, Canada's researchers will play a meaningful role on the global stage and contribute significantly to the quality of life today and for generations tocome."

The more than $3 million going to Mac researchers will help advance their work in health, materials and electrificationresearch.

Projects at Mac that will benefit from the fundinginclude:

Faculty ofEngineering

Bilgen Berker, Electrical and Computer Engineering Project: An Acoustic Noise and Vibration Measurement Facility for Low-noise and High-efficiency Electric Motor DrivesAward:$200,000

Ryan Lewis, Engineering Physics Project: Advanced Epitaxial Nanostructures and Materials LaboratoryAward:$190,584

Zahra Keshavarz-Motamed, Mechanical Engineering Project: Developments of Diagnostic and Predictive Tools and Regulatory Device Testing Machines for Cardiovascular DiseasesAward:$185,000

Maureen Lagos Paredes, Materials Science & Engineering Project: Momentum-resolved EELS Spectroscopy of Beam-sensitive Nanoscale MaterialsAward:$387,788

Faculty of HealthSciences

Lisa Carlesso, Rehabilitation Science Project: Understanding Pain Mechanisms and Management in Neuromusculoskeletal RehabilitationAward:$129,000

Michael McGillion, Nursing Project: Improving Perioperative and canceR Outcomes Through Excellence and appliCation of Virtual Technologies (PROTECT) LabAward:$800,000

Ishac Nazy, Medicine Project: Investigating Novel Mechanisms in Immune-mediated Platelet DisordersAward:$160,000

Michael Surette, Medicine Project: Metagemomics and Genomics of the Microbiome, Infectious Disease and Host ResponseAward:$650,000

Faculty ofScience

Katherine Bujold, Chemistry & Chemical Biology Project: Establishment of Nucleic Acid Nanomedicine Laboratory at McMaster UniversityAward:$75,005

Katrina Choe, Psychology, Neuroscience & Behaviour Project: Neural Mechanisms Linking Autism-risk Genes with Impaired Social BehaviorAward:$400,000

Jeremy Walsh, Kinesiology Project: Integrative Psychophysiology Research LabAward:$100,000

A full list of research projects and funding recipients benefitting from this investment can be found on the CFI website.

Original post:
McMaster University researchers awarded more than $3M in Federal funds for projects - insauga.com

The Value of Plain Language Summaries to Patients and Caregivers – The Voice Online

AS HEALTH professionals make diagnoses every day, patients around the world take to their keyboards to research their newfound conditions. But how often is the information that these patients need accessible to them? Most journals only publish articles written for specialist readers. However, with publications now becoming increasingly accessible, patients are reading medical publications in the hope that they can better understand how to manage their conditions and/or the treatments that could be available to them.

This is where the scientific and medical publisher Future Science Group has stepped in. The progressive publisher has recognised the unmet need for patient-oriented resources and, over the past couple of years, has started publishing plain language summaries (PLS) of technical publications in its peer-reviewed journals.

What Are Plain Language Summaries?

PLS are concise recaps of technical publications. Written for lay audiences, they unpack the complex data, jargon, and concepts covered in these publications, breaking these down into their simplest terms. The summaries blend plain language with a range of media inclusions, like infographics, videos, and audio so that non-specialist readers can understand the latest developments in specific conditions, treatments, and therapies.

Here, Future Science Group reflects on two recent studies that assess a) to what extent patients read medical publications and b) how patients use the information in these publications to manage their conditions.

Do Patients Read and Use Peer-Reviewed Medical Publications?

One example of a study into how patients research their conditions is a study conducted by the healthcare marketing research company Adelphi Research. During this study, the research team asked 100 patients who have atopic dermatitis (eczema) and 50 patient caregivers to complete a survey on the information sources they use to research the condition.

Patient Survey Responses

The study, which took place in the U.S., noted that 35% of its respondents had a college education and 33% had a graduate school education. 81% of these respondents had carried out online research to investigate their condition, 77% had accessed information from healthcare providers, and 67% had sourced medical research articles themselves. Of those familiar with medical publications, 37% actively searched for these publications, while 90% accessed freely available articles.

62% of the respondents accessed medical publications via a general internet search.

49% accessed scientific journals.

19% sourced information from a library.

13% found information on patient organisation websites.

12% found information using the free search engine PubMed.

However, only 53% of respondents felt at least relatively confident in their understanding of the medical publications. Approximately half of the respondents didnt feel the publications empowered them to get involved in decision-making processes related to their eczema or stay up to date with the latest developments surrounding their condition.

Fewer than half of the respondents felt the publications empowered them to:

Optimise their disease management.

Discuss alternative treatments with healthcare professionals.

Control their condition.

Adhere to their treatment plans.

The results of this study emphasise the clear need for peer-reviewed medical content written for patient audiences. Most scientific journals lack clarity for lay audiences, and theyre often difficult to understand. However, Plain language summaries offer a valuable solution through simple language, clear structure, and media inclusions that make difficult concepts easier to grasp for patients who want to learn more about their conditions.

What Is the Value and Feasibility of Developing Plain Language Summaries of Peer-Reviewed Articles for Patients?

Another study, this one published in Therapeutic Innovation & Regulatory Science, also involved a survey that investigated whether and how patients research their conditions. Like the Adelphi Research study, this research involved a survey that confirmed patients regularly research health-related information online: 61% of the study respondents performed general internet searches on their conditions, 57% accessed patient-specific websites, and 47% searched for articles from scientific journals.

Patient Survey Responses

55 patients provided complete responses to the survey, reporting on a variety of diseases. While 23% reported on diseases concerning the central nervous system and neurology, 22% reported on pain and inflammation, 17.5% reported on autoimmune diseases, and 17.5% reported on cancers. Most of these patients consulted physicians for information about their conditions: 62% consulted specialists, 30% consulted general practitioners, and 5% consulted nurses. That said, only 17.5% of patients relied solely on a healthcare professional for information. Most also performed general internet searches, visited patient organisation websites, and accessed print and electronic scientific journals.

Almost all patients who took part in the study agreed that they wanted their physicians to discuss new information about their conditions and possible treatments with them. While 69% reported that they wanted their doctor to share all information with them, 29% reported that they only wanted their doctor to share information that was specifically relevant to them. The remaining 2% felt that information share would be of interest but that they would find it acceptable for their doctor not to share information.

Furthermore, while 96% of the patients concluded that they would be interested in sharing health information that they had found with their doctor, 45% noted that they would only feel comfortable discussing such information if they had a solid enough understanding of the material to have a conversation about it.

To conclude, 98% of patients either agreed or strongly agreed that health-related information should be easily understandable and more accessible to patients.

Patient and Caregiver Interviews

The study also involved interviews with patients and caregivers, during which patients explained that the main reasons they were researching their conditions were to improve their knowledge of their conditions and empower themselves. All interviewees noted that they would like doctors to provide more information, especially as information from the internet isnt always reliable.

Some of the information that patients hoped to gain from their doctors included information on how their disease and its management can affect daily living, epidemiologic data that offers long-term prognostic information about their disease, and information on the relevance of data from clinical studies. The respondents also agreed that handing out PLS could help doctors build good relationships with their patients while offering reliable and trustworthy resources.

Physician Insights

Meanwhile, the physicians who took part in the study concluded that PLS play an important role in improving patient communication, especially given the limited time available during many consultations. As a result, 60% of physician respondents confirmed that they would use PLS in their patient communications.

Open-access publishing and the expansion of online platforms should make communication through PLS even easier over upcoming years. This is essential given new patient engagement concepts (like shared decision making (SDM), self-management, patient empowerment, and patient-centred care), which have been widely adopted in clinical practice over the past few years. These concepts are key to helping patients become more involved in their healthcare management.

How Plain Language Summaries Fill the Demand for Patient-Centred Resources

The advent of PLS and other patient-centred resources has fuelled the evolution of the historically paternalistic relationship between patients and healthcare professionals into a collaborative partnership. The studies discussed here reinforce the evidence that patients actively seek information about their conditions to complement the information they receive from healthcare professionals, and that there is demand for plain language content written for patient audiences.

Future Science Groups publication of PLS in its open-access journals works towards filling this demand, which is only growing. These summaries prove invaluable to both patients and healthcare professionals, playing an essential role in patient dialogue, education, and accessibility.

About Future Science Group

Future Science Groups highly regarded journals publish the latest information in a wealth of scientific and medical disciplines, spanning from oncology to regenerative medicine to nanomedicine. Aside from publishing its portfolio of 34 journals, the Group also hosts a variety of events and digital hubs, where scientific communities come together to partake in essential discussions that support developments in science and medicine.

Future Science Group has been praised for its PLS initiative, which makes clinical study results and other essential information accessible to lay audiences, ensuring that all readers can access resources that help them understand diseases, treatments, and therapies.

Read more from the original source:
The Value of Plain Language Summaries to Patients and Caregivers - The Voice Online